

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Justin M. Long¹ and David M. Holtzman^{1,*}

¹Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA

*Correspondence: holtzman@wustl.edu
<https://doi.org/10.1016/j.cell.2019.09.001>

Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular β -amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clinical trials have failed to demonstrate benefits. Here, we review recent advances in our understanding of AD pathobiology and discuss current treatment strategies, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.

Dementia describes an intra-individual pattern of decline in memory and thinking impairing at least two domains of cognition (McKhann et al., 2011). Alzheimer disease (AD) is the most common cause of dementia. The majority of cases occur after age 65, constituting late-onset AD (LOAD), while cases occurring earlier than age 65 are considerably rarer, constituting less than 5% of all cases and are termed early-onset AD (EOAD) (Alzheimer's Association, 2019). Approximately 1%–2% of AD is inherited in an autosomal dominant fashion (ADAD) and can present with very early age of onset and a more rapid rate of progression, and it is sometimes associated with other neurologic symptoms seen less frequently in sporadic AD (Bateman et al., 2012). Clinical syndromes consistent with AD are defined by classical symptoms and cognitive profiles. However, AD as a distinct entity is now defined biologically by the presence of a specific neuropathological profile (Jack et al., 2018a): extracellular deposition of β -amyloid ($A\beta$) in the form of diffuse and neuritic plaques and the presence of intraneuronal neurofibrillary tangles (NFTs) and neuropil threads within dystrophic neurites consisting of aggregated hyperphosphorylated tau protein (Duyckaerts et al., 2009).

Dementia due to AD is associated with the onset of significant and progressive disability throughout the disease course, with death an inevitable outcome generally occurring within 5–12 years of symptom onset (Vermunt et al., 2019). The burden on caregivers and the public health sector is enormous (Alzheimer's Association, 2019). There is a dire need for disease-modifying therapies that may prevent or slow the rate of disease progression, but unfortunately none are currently available. The history of pharmaceutical development for AD has been plagued by a seemingly endless parade of mid-to-late-stage clinical trial failures. Nonetheless, significant strides have been made in recent years in clarifying key aspects of the underlying pathobiology of AD.

Though the therapeutic pipeline has faced struggles and some pharmaceutical companies have chosen to abandon their AD drug development divisions, novel therapeutic strategies are still being actively developed and tested. This Review discusses recent advances in our understanding of the pathobiology of AD and summarizes treatment strategies as well as the challenges and opportunities on the path to development of truly disease-modifying treatments.

Clinical and Preclinical Disease

Symptomatic AD follows an insidious and progressive course. Typical amnesic cases are characterized by early impairment in learning and memory, followed by later impairments in complex attention, executive function, language, visuospatial function, praxis, gnosis, and behavior and/or social comportment (McKhann et al., 2011). Symptomatic AD may also present as atypical clinical syndromes in which there is early impairment in non-memory domains. Posterior cortical atrophy presents with early deficits in visuospatial function, praxis, and gnosis (Tang-Wai et al., 2004). Logopenic variant of primary progressive aphasia is characterized by dysfluent language with prominent word-finding impairment and severe impairment in repetition (Gorno-Tempini et al., 2008). The behavioral/dysexecutive variant of AD presents with early executive dysfunction or behavioral impairment (especially apathy, hyperorality, and perseveration) (Ossenkoppele et al., 2015). Clinical dementia severity can be graded by use of standardized instruments such as the Clinical Dementia Rating (CDR) (Burke et al., 1988; Morris, 1997), which grades disease severity based on composite level of dysfunction in domains of memory, orientation, judgement and problem solving, involvement in community affairs, function in home and hobbies, and self-care.

Antemortem AD neuropathologic diagnoses can now be made with reasonable validity using cerebrospinal fluid (CSF)






Figure 1. Timing of Major AD Pathophysiological Events in Relation to Clinical Course

A protracted preclinical phase of disease is characterized by the early onset of amyloid deposition. This is detected by a reduction in CSF and plasma levels of A β 42 or increased global signal on amyloid PET imaging. Concurrently, there are early neuroinflammatory changes (such as microglial activation). Microgliosis can be detected longitudinally via use of PK11195 PET imaging, though better agents are needed. This is followed by the spread of neurofibrillary tangle (NFT) tau pathology from the medial temporal lobes into neocortex. Increased signal on tau PET imaging and increased CSF phospho-tau levels mark this change in patients. Synaptic dysfunction, synapse loss, and neurodegeneration accumulate with pathologic spread of tau aggregates. Imaging analysis of hippocampal and cortical volumes allows for longitudinal tracking of neurodegenerative changes. Onset and progression of cognitive impairment correlates with accumulation of tau

and hippocampal volume loss but not amyloid deposition. Onset and severity of clinical symptoms in AD can be staged by use of the Clinical Dementia Rating (CDR) scale, where a score of 0 indicates normal cognition and scores of 0.5, 1, 2, and 3 indicate questionable, mild, moderate, and severe dementia, respectively.

or positron emission tomography (PET) imaging biomarkers as surrogate markers for cerebral A β and tau deposition (Brier et al., 2016; Fagan et al., 2006, 2007; Lowe et al., 2019; Morris et al., 2009). Recent studies demonstrate the ability to detect CNS A β deposition via the use of plasma assessment of A β species (Nakamura et al., 2018; Ovod et al., 2017; Palmqvist et al., 2019). Longitudinal studies of cognitive function and CSF and neuroimaging biomarker changes in ADAD and LOAD have identified a significant preclinical phase of disease preceding onset of clinical symptoms by at least 10–20 years (Vermunt et al., 2019), characterized by early deposition of A β in the precuneus and other cortical regions comprising the default mode network, followed sequentially by regional cortical hypometabolism, accumulation of tau pathology, hippocampal volume loss, and onset of symptomatic cognitive impairment (Figure 1; Bateman et al., 2012; Fagan et al., 2006, 2007, 2014; Gordon et al., 2016, 2018; Hanseeuw et al., 2019; Jack and Holtzman, 2013; Morris et al., 2009; Vos et al., 2013). Synaptic and neuronal loss in the entorhinal cortex generally correlates well with onset of cognitive impairment (Gómez-Isla et al., 1996). CSF and plasma neurofilament light chain (NfL) is an emerging biomarker that appears to track the level of general neurodegeneration across all forms of neurodegenerative dementias (Bridel et al., 2019; Mielke et al., 2019). Studies of both ADAD and LOAD have demonstrated that rate of change in CSF and plasma NfL levels correlates with cortical thickness on structural MRI and cognitive performance (Mattsson et al., 2019; Preische et al., 2019).

Pathophysiology of AD Amyloid

A β peptide was first identified as the primary constituent of meningo-vascular amyloid in 1984 (Glenner and Wong, 1984) and subsequently as the main constituent in amyloid neuritic plaques (Masters et al., 1985). Over the ensuing decades, enormous research efforts were expended to clarify the underlying biology of this peptide and its role in AD pathophysiology. A β is produced

by sequential cleavage of β -amyloid precursor protein (APP) by β -secretase and γ -secretase (Figure 2A; for review, see Haass et al. [2012]). The β -secretase enzyme (BACE1) cleaves APP at the N terminus of the A β sequence, releasing secreted APP- β and the membrane-bound C99 fragment (Vassar et al., 1999). The γ -secretase complex consists of four protein subunits: presenilin (PSEN), presenilin enhancer (PEN), APH, and Nicastrin. There are multiple isoforms of PSEN (PSEN1/PSEN2) and APH (APHA, APH B/C); up to four different γ -secretase complexes may exist in single cell (Voytyuk et al., 2018; Xia, 2019). Following cleavage by BACE1, the γ -secretase complex binds to N-terminally cleaved APP fragment (C99) and intramembranously cleaves at the ϵ -site releasing C-terminal fragment (CTF) and A β 48. The γ -secretase complex then processes along the remaining A β C-terminal end, producing sequentially shorter peptides until the A β peptide is released from the complex (generally after producing peptides 38-, 40-, and 42-amino acids in length). Recent publication of high-resolution substrate-enzyme cryogenic electron microscopy (cryo-EM) molecular structures for γ -secretase-APP C83 fragment and γ -secretase-Notch 100 fragment (Yang et al., 2019; Zhou et al., 2019) has definitively determined substrate binding sites for γ -secretase and lends strong evidence for a helix-unwinding model of sequential substrate processing. BACE1, γ -secretase, and APP form a large molecular complex *in vivo*, suggesting that A β production may be facilitated by directly shuttling APP from one processing enzyme to another (Liu et al., 2019). A β is produced predominantly in endosomes, and its release from neurons is modulated by synaptic activity (Kamenetz et al., 2003; Wei et al., 2010) both presynaptically (Cirrito et al., 2005, 2008) and postsynaptically (Verges et al., 2011).

A β peptides are prone to aggregate into β sheet conformations in the form of higher-order oligomers, protofibrils, and fibrils, which are detectable in AD brain. Owing to increased hydrophobicity of its expanded C terminus, A β 42 has a greater propensity for aggregation. Recent cryo-EM experiments have elucidated the structure of synthetically derived A β 42 fibrils, demonstrating




Figure 2. Selected Roles of A β and Tau in AD Pathophysiology

(A) A β is derived from APP via the proteolytic functions of BACE1 and γ -secretase. BACE1 and APP are co-localized to endosomes, which is the location of intracellular A β production. A β is secreted into the interstitial fluid via a pathway that is enhanced in the setting of neuronal activity. Following secretion, A β aggregates into higher-order oligomers and fibrils that have numerous effects on cellular function including impaired synaptic activity and synapse loss, impaired cerebral capillary blood flow, and direct promotion of tau pathology by stimulating tau hyperphosphorylation as well as other pathways.

(B) Pathological tau aggregation (blue shading) in the medial temporal lobes occurs with aging and is not always associated with cognitive impairment (primary age-related tauopathy). The earliest accumulation of A β deposition (red shading) is in the precuneus and posterior cingulate. Longitudinal CSF and imaging biomarker studies suggest that global amyloid accumulation is required for the pathologic spread of tau from the medial temporal lobes to other cortical regions in AD. In this way, AD may represent an amyloid-facilitated tauopathy.

(C) Pathologic spread of tau aggregates in AD usually occurs in a stereotyped fashion along neuroanatomically connected networks. Misfolded tau likely acts in a prion-like manner to promote templated misfolding of native monomers, leading to seeding of new pathological tau aggregates. Tau pathology can subsequently spread *trans*-synaptically to distant neurons, representing a molecular correlate for pathologic tau spreading noted in human AD brain.

whereas oligomers appear to be detectable among the halo of dystrophic neurites surrounding neuritic plaques (Masters and Selkoe, 2012). There is evidence that the process of A β aggregation may require A β uptake by microglia followed by intracellular seeding and aggregation (Sosna et al., 2018).

A β fibrillization can be “seeded” in a prion-like manner by the presence of small assemblies of misfolded β sheet-containing A β seeds that template the formation of larger amyloid aggregates (Walker and Jucker, 2015). Brain extracts containing minute amounts of misfolded A β prepared from AD brain or APP transgenic mice, when injected into APP transgenic animals via intracerebral or intraperitoneal routes, will induce cerebral amyloidosis (Eisele et al., 2009, 2010; Ye et al., 2015). There is strong evidence that human-to-human transmission of

7 nm diameter fibrils containing two twisted protofibrils consisting of A β 42 monomers assuming an “LS” shape stacked in parallel with in-register cross- β structure (Gremer et al., 2017). 8 nm amyloid fibrils are present in the center of neuritic plaques,

amyloid pathology is possible. Patients who developed iatrogenic Creutzfeldt–Jakob disease (CJD) following injections of prion-contaminated growth hormone derived from pooled cadaveric pituitary extracts prior to 1985 have been found in

some cases to have significant cerebral and vascular amyloid pathology (conophilic amyloid angiopathy [CAA]) (Jaunmuktane et al., 2015). When injected intracerebrally into APP transgenic mice, these extracts are able to seed CAA pathology and cerebellar amyloid deposition (Purro et al., 2018).

Based on a number of lines of evidence, Hardy and Higgins proposed the amyloid cascade hypothesis in 1992, positing that deposition of A β in the brain is the initiating step of AD pathogenesis, leading to subsequent tau deposition, neuron and synaptic loss, and cognitive decline (Hardy and Higgins, 1992). This hypothesis has been the leading model of AD pathogenesis since it was first proposed, although portions have been revised or supplemented over time (Musiek and Holtzman, 2015; Selkoe and Hardy, 2016). The hypothesis is supported by the discovery that exclusively genetic forms of AD, such as ADAD, Down syndrome (trisomy 21), or APP locus duplications, produce an increase in the A β 42/40 ratio, total A β production, or A β fibrillinogenic properties and are sufficient to induce typical AD pathology (Tcw and Goate, 2017). Also, a rare APP mutation A673T that reduces risk of developing AD causes decreased A β production (Jonsson et al., 2012; Martiskainen et al., 2017). In addition, the strongest genetic risk factor for LOAD, apolipoprotein E (APOE), in large part appears to increase risk via influencing A β seeding and clearance (Bales et al., 1997; Castellano et al., 2011; Verghese et al., 2013). While the genetic evidence strongly supports the importance of A β aggregation in instigating the AD cascade, it seems clear that A β is necessary but not sufficient and that there are other downstream factors that play a key role. For example, there is minimal correlation between phases of amyloid deposition and degree of cognitive decline (Nelson et al., 2012). Also, patterns of regional cerebral amyloid deposition do not correlate with patterns of regional cerebral hypometabolism on functional neuroimaging (Altmann et al., 2015; Edison et al., 2007), although a recent study suggests that regional amyloid deposition does correlate with distant regional hypometabolism, suggesting that amyloid reduces the metabolic activity of distant neurons projecting to regions of amyloid deposition (Pascoal et al., 2019). Finally, despite decades of investment by the pharmaceutical industry in anti-amyloid therapies and numerous phase 3 clinical trials, no amyloid-targeting therapy has been successful in limiting progression of cognitive impairment in symptomatic AD. These data suggest that while amyloid accumulation may be key in beginning the pathological process, other downstream events, such as neuroinflammation and tau accumulation, may be the main drivers of neurodegeneration.

One extension of the amyloid hypothesis is the “cellular phase” of AD, proposed by Bart De Strooper and Eric Karran (De Strooper and Karran, 2016). This extension proposes that accumulation of cerebral amyloid and tau pathology (the “biochemical phase”) is a slow, gradual process that is tolerated by CNS cells early in the course of disease, serving as a risk factor for development of clinical disease, but that the disease only manifests clinically when cellular homeostatic mechanisms fail, leading to impaired clearance of aggregated pathologic protein (proteopathy), increased cellular stress, and a complex breakdown of finely tuned intercellular physiologic functions that ultimately lead to neurodegeneration. Specifically, the cellular

phase is characterized by dysfunction of the neurovascular unit, aberrant neuronal network activity, and impaired astrocyte and microglia homeostatic functions and/or possible gain-of-toxic functions.

Several lines of evidence suggest A β deposition may be required for progression of tau pathology in AD (Figure 2B). Neuropathological studies in humans have demonstrated that tau pathology generally does not progress from the entorhinal cortex into the neocortex in the absence of co-occurring amyloid pathology (Pontecorvo et al., 2019; Price and Morris, 1999; Price et al., 2009; Wang et al., 2016). Longitudinal assessment of amyloid and tau PET imaging suggests that the rate of amyloid accumulation predicts onset of tau accumulation whereas the rate of tau accumulation predicts onset of cognitive impairment (Hansseuw et al., 2019). A study of tau kinetics in humans and cell culture using stable isotope labeling techniques demonstrates that tau production correlates with the presence of amyloid, suggesting a mechanistic link (Sato et al., 2018). A three-dimensional (3D) *in vitro* culture system consisting of human neurons differentiated from induced pluripotent stem cells (iPSCs) overexpressing human APP containing FAD mutations generates robust A β 42 production and amyloid deposition. Importantly, this model also develops elevated phospho-tau levels and fibrillary tau aggregates, suggesting that elevated A β levels alone are sufficient to drive tau pathology in human neurons (Choi et al., 2014). Multiple studies have assessed the effect of combined A β deposition on local tau pathology by either crossing tau transgenic and APP transgenic mice or by injecting A β 42 fibrils into tau transgenic mice. In these studies, tau pathology and neurodegeneration are enhanced in mice harboring both pathologies, whereas amyloid pathology is generally unaffected by concurrent tau pathology (Bolmont et al., 2007; Götz et al., 2001; Hurtado et al., 2010; Lewis et al., 2001; Pooler et al., 2015). This was demonstrated in a recent study where intracerebral injection of tau fibrils derived from human AD brain into A β plaque-bearing mice led to seeding of aggregated human tau in periplaque dystrophic neurites followed by development of NFTs (He et al., 2018).

A β may also lead to cognitive impairment in ways independent from its effects on tau. Soluble oligomers isolated from AD brain have been shown to potently inhibit long-term potentiation (LTP), enhance long-term depression (LTD), and reduce dendritic spine density in rodent hippocampal slice cultures (Kamenetz et al., 2003; Shankar et al., 2007; Wei et al., 2010). They also cause impairment in cognitive tasks when injected into the lateral ventricles of rodent models (Shankar et al., 2008). It is unclear whether soluble oligomers in human AD brain mediate synaptotoxic effects sufficient to cause cognitive impairment. One issue is that it is difficult to determine whether soluble oligomers definitively exist *in vivo* due to technical challenges related to the biochemical extraction procedures required to detect them. A recent study shows that the presence of A β also causes capillary constriction in human cortical slices by acting on pericytes to generate reactive oxygen species (ROS), leading to endothelin-1 release (Nortley et al., 2019). A β may also lead to reduced cerebral blood flow by inducing neutrophils to occlude and stall capillary flow (Cruz Hernández et al., 2019). Hypoxia can induce increased A β production, possibly via increased BACE1 expression (Sun et al., 2006), suggesting the possibility of a pathological feedforward loop.

In summary, the available data still strongly support the central role of pathologic A β accumulation in mediating AD pathogenesis as outlined in the original description of the amyloid cascade hypothesis, although its mechanism may be less direct than originally anticipated and requires further clarity via ongoing studies.

Tau

Multiple lines of evidence suggest that aggregated, hyperphosphorylated forms of tau may be a primary driver of neurodegeneration in AD. Clinico-neuropathologic correlation analyses have demonstrated that tau pathology propagates throughout the AD brain in a stereotyped fashion across neuroanatomically connected networks (Figure 2C), forming the basis of Braak staging (Braak and Braak, 1991). However, recent cross-sectional and longitudinal tau-PET imaging studies in cognitively normal amyloid-positive individuals demonstrate widely distributed and continuous accumulation of tau pathology outside of the entorhinal cortex, suggesting that tau propagation may not be as spatially restricted as previously thought (Jack et al., 2018b; Schultz et al., 2018). Unlike A β , the stage of tau pathology correlates well with the progression of cognitive impairment (Giannakopoulos et al., 2003; Nelson et al., 2012). With age, tau pathology accumulates in the entorhinal cortex and medial temporal lobes, even in the absence of cognitive decline—this is termed primary age-related tauopathy (PART) (Craty et al., 2014). Cognitive impairment in AD is only noted when tau spreads from the entorhinal cortex into the neocortex in neuropathological studies (Price and Morris, 1999; Price et al., 2009). On longitudinal and cross-sectional studies of tau- and amyloid-PET imaging combined with structural MRI, only the presence or accumulation of tau was a predictor of cognitive impairment, whereas the presence or accumulation of amyloid was a predictor of more severe tau-associated cognitive impairment (Aschenbrenner et al., 2018; Hanseeuw et al., 2019). These findings have led to the hypothesis that cognitive decline and neurodegeneration in AD is primarily driven by onset and spread of tau pathology.

Tau protein is encoded by *MAPT* gene on chromosome 17, is primarily expressed by neurons in the brain, and is alternatively spliced at the N-terminal domain (N) and microtubule-binding repeat domain (R) to form six distinct isoforms (0N3R, 0N4R, 1N3R, 1N4R, 2N3R, and 2N4R), which are differentially expressed during brain development. Although NFTs in AD contain both 3R and 4R isoforms, different tau isoforms are over-represented in pathological aggregates in other human tauopathies (Guo et al., 2017). The physiological role of tau in the CNS is not entirely clear, although numerous *in vitro* experiments have documented important roles in microtubule assembly, stabilization of neuronal axons, and regulation of microtubule transport (Dixit et al., 2008; Weingarten et al., 1975). However, tau knockout (KO) mice do not have a severe developmental phenotype (van Hummel et al., 2016) but do exhibit subtle deficits such as delayed neuronal maturation in cell culture (Dawson et al., 2001) and impaired synaptic plasticity (Ahmed et al., 2014).

Tau protein is subject to numerous post-translational modifications, including phosphorylation, acetylation, glycation, O-GlcNAcylation, nitration, SUMOylation, ubiquitination, and truncation (Marcelli et al., 2018). Tau can be phosphorylated at 85 different residues (Guo et al., 2017). Pathological types

and patterns of tau phosphorylation can occur even prior to development of NFT. In many cases, aberrant phosphorylation results in decreased binding affinity for microtubules (Biernat et al., 1993; Mandelkow et al., 2007). This disassembly increases the cytosolic pool of tau and is thought to promote aggregation and fibrillization. Hyperphosphorylated tau is also redirected from the axonal compartment to the somatodendritic compartment where it can impair synaptic function by inhibiting glutamate receptor trafficking or synaptic anchoring (Hoover et al., 2010). Tau acetylation has been shown to reduce degradation of phosphorylated tau and increase tau pathology (Min et al., 2010) but has also been shown to inhibit tau phosphorylation at certain residues and limit further aggregation (Cook et al., 2014). Tau acetylation has also been shown to result in axon initial segment cytoskeletal instability followed by mislocalization of tau to the somatodendritic compartment (Sohn et al., 2016). O-GlcNAc modification of tau inhibits toxic self-assembly (Ryan et al., 2019).

There are a number of tau kinases that mediate tau phosphorylation. They comprise three groups—proline-directed serine-threonine protein kinases, non-proline directed serine-threonine protein kinases, and tyrosine protein kinases. Examples include glycogen synthase kinase (GSK) 3, cyclin-dependent kinase-5 (Cdk5), mitogen-activated protein kinase (MAPK), cAMP-dependent protein kinase A (PKA), and calcium-calmodulin-dependent protein kinase II (CaMKII), among many others (Guo et al., 2017). Various kinases have been proposed as putative drug targets for AD.

Tau is generally a soluble protein that is natively unfolded but under the right conditions will aggregate into oligomers and fibrils. NFT and neuropil threads contain an insoluble form of tau aggregated into β sheet-containing amyloid fibrils, known as paired helical filaments (PHFs) (Crowther and Wischik, 1985; Kidd, 1963; Mandelkow et al., 2007). These aggregated fibrils are known to be polymorphic (Frost et al., 2009) and differ in conformation when derived synthetically or from brains of patients with various tauopathies. (Guo et al., 2016; Sanders et al., 2014). Recent cryo-EM structures of tau fibrils derived from brains of AD patients (Fitzpatrick et al., 2017) and other tauopathies have demonstrated unexpected insights into fibril structures and confirm that synthetic tau fibrils assume a vastly different folded structure as compared to AD brain-derived tau fibrils (for review, see Lippens and Gigant [2019]).

Since tau is normally highly soluble in its native monomeric form and does not have significant intrinsic hydrophobicity, the question arises as to what prompts tau aggregation in disease. Numerous studies over the last decade have demonstrated the prion-like ability of aggregated human tau fibrils to self-propagate, for both synthetically prepared fibrils and those derived from human AD brain. Exogenously supplied fibrils will seed aggregation of transgenic human and endogenous mouse tau fibrils in mouse tauopathy models by enhancing nucleation of new fibrils. These aggregates then spread transsynaptically to remote, anatomically connected brain regions, inducing further seeding and aggregation, similar to the pathologic spread of tau noted in AD brain (de Calignon et al., 2012; Clavaguera et al., 2009, 2013; Frost et al., 2009; Iba et al., 2013; Liu et al., 2012). Thus, prion-like seeding and spreading may represent a

mechanism whereby tau pathology propagates from the entorhinal cortex to the neocortex in AD (DeVos et al., 2018).

ApoE

ApoE protein is an apolipoprotein whose major function is to serve as a lipid-binding protein in lipoprotein particles and participate in transport and delivery of lipids to target sites. ApoE is expressed at the highest levels in the liver and brain. In the brain, ApoE is expressed primarily in astrocytes and to a lesser degree in microglia.

APOE is the strongest genetic risk factor for LOAD (Corder et al., 1993; Strittmatter et al., 1993). The strength of this association has been confirmed in numerous clinical, pathological, epidemiological, genome-wide association (GWASs), and whole-genome sequencing studies over the years (Kunkle et al., 2019). The APOE gene has three common alleles encoding three protein isoforms—ApoE2, ApoE3, and ApoE4—which differ in sequence by single amino acid substitutions at two different residues (E2 cys112/cys158, E3 cys112/arg158, and E4 arg112/arg158). A single inherited copy of the APOE ϵ 4 allele increases risk of developing LOAD by ~3- to 4-fold, while two inherited copies increases risk by ~12-fold (Roses, 1996). Inheritance of the APOE ϵ 2 allele is protective. Longitudinal CSF, MRI, and PET imaging studies of the preclinical phase of AD have established that APOE ϵ 4 allele carriers develop enhanced cerebral amyloid deposition with age, do so at an earlier age, and accumulate amyloid at a more rapid rate relative to non-carriers (Bussy et al., 2019; Grimmer et al., 2010; Mishra et al., 2018; Morris et al., 2010; Risacher et al., 2015). The effect of APOE ϵ 4 on measures of tau accumulation and hippocampal atrophy are less certain. ApoE has additionally been implicated in numerous AD-relevant neurobiological processes, many of which are mediated differentially by ApoE isoforms, likely contributing to its role in AD pathogenesis (Figure 3).

ApoE likely regulates AD risk in large part via effects on amyloid pathology (Figure 3A; Huynh et al., 2017a). ApoE directly binds to A β present in plaques (Namba et al., 1991). APP transgenic animal models demonstrate markedly reduced fibrillar A β deposition and A β levels in the setting of ApoE KO, suggesting ApoE inhibits clearance and/or promotes A β seeding (Bales et al., 1997, 1999; Bien-Ly et al., 2012; Huynh et al., 2017b; Kim et al., 2011; Liu et al., 2017; Ulrich et al., 2018). In APP transgenic-ApoE targeted replacement (ApoE-TR) mice, where human ApoE isoforms are expressed under the influence of endogenous murine ApoE regulatory sequences, ApoE isoforms have differential effects on amyloid pathology. ApoE4-TR mice have enhanced amyloid deposition and higher A β levels (Bales et al., 2009). Studies on the effects of ApoE on A β production are conflicting. In one study where iPSC-derived human neurons were co-cultured with mouse glia expressing human ApoE isoforms, neuronal A β production was significantly increased in ApoE4 glia co-cultures (Huang et al., 2017). However, this effect was not observed in other studies using different culture systems. (Biernat et al., 1995; Cedazo-Minguez et al., 2001). Experiments where ApoE expression is controlled temporally, either via inducible expression or via the use of intrathecal antisense oligonucleotides (ASOs), highlight that ApoE promotes the initial seeding of fibrillar A β deposition, whereas subsequent plaque growth after seeding seems to rely on other factors (Huynh et al., 2017b; Liu et al., 2017). Detailed

in vivo microdialysis and stable isotope labeling kinetics experiments have demonstrated that ApoE regulates clearance of A β in the brain in an isoform-dependent manner (ApoE4-TR mice have diminished A β clearance relative to other TR mice), whereas A β production was not influenced by ApoE isoform (Castellano et al., 2011). Although it was initially postulated that ApoE regulates clearance via direct interactions with A β , in fact, there is little direct binding of monomeric, soluble A β with ApoE *in vivo*. Instead, ApoE regulates clearance of A β by competitively binding to A β receptors, such as LDLR-related protein 1 (LRP1) on the surface of astrocytes, and blocking A β uptake. In this way, ApoE KO mice exhibit the highest rates of clearance since there is no competition with A β receptors (Verghese et al., 2013). Possible routes of A β clearance include astrocytic uptake (Basak et al., 2012), microglial phagocytosis (Heckmann et al., 2019), blood-brain barrier transport (Castellano et al., 2012; Zlokovic, 2013), glymphatic clearance (Iliff et al., 2012), and meningeal lymphatics (Da Mesquita et al., 2018).

ApoE also has modulatory effects on tau pathology and tau-related neurodegeneration (Figure 3B; Shi and Holtzman, 2018). Tau binds to ApoE3 but not ApoE4 *in vitro* (Strittmatter et al., 1994). In a recent study assessing the effect of ApoE-TR in the PS19 (tauP301S) tauopathy mouse model, ApoE4 dramatically exacerbated tau-mediated neurodegeneration (Shi et al., 2017). ApoE genetic deletion significantly reduced the extent of neuron and volume loss in PS19 mice and strongly attenuated microglial and astrocyte activation. A recent study failed to replicate the neurotoxic effect of ApoE4 in tauopathy mice. In this study, AAV viral transduction was used at postnatal day 0 to overexpress tauP301L in ApoE-TR mice. They found that ApoE2 mice, rather than ApoE4, had enhanced tau pathology, astrogliosis, and behavioral impairment (Zhao et al., 2018). Of note, neurodegeneration was not observed in this model at 6 months of age, the time of endpoint analysis. Therefore, discrepancies between these studies are likely explained by differences in experimental models.

ApoE4 may mediate risk for AD through modulation of immune and microglial responses. APOE ϵ 4 carriers have a stronger systemic inflammatory response to an intravenous lipopolysaccharide (LPS) challenge, including more intense hyperthermia and higher levels of tumor necrosis factor (TNF) secretion in whole blood (Gale et al., 2014). ApoE expression in microglia is required for the phenotypic expression of disease-associated microglia (see Neuroimmune Activation below). ApoE also promotes microglial clustering around A β plaques, and in the absence of ApoE expression, there is strong reduction in the total amount of fibrillar plaques and plaque size but an increase in overall A β -immunoreactive deposits (Figure 3C). Plaques appear less compact with fewer periplaque microglia and enhanced neuritic dystrophy (Ulrich et al., 2018). ApoE is also required for microglial intracellular endolytic degradation of A β by neprilysin and insulin-degrading enzyme (Jiang et al., 2008). This suggests that ApoE plays an important role in mediating the microglial response to A β plaques.

ApoE4 may have direct pathologic effects on neurons and neuronal networks independent of effects on amyloid and tau pathology (Figure 3D; Najm et al., 2019). In primary neuronal cell culture, exogenously applied ApoE4 directly inhibits neurite




Figure 3. Postulated Roles of ApoE in AD Pathophysiology

(A) ApoE enhances seeding and fibrillization of A β , leading to enhanced amyloid deposition. ApoE (especially E4) impedes A β clearance from brain parenchyma by competitively binding to A β receptors on glial cells.

(B) ApoE (especially E4) enhances tau pathogenicity. Presence of ApoE leads to increased microglial and enhanced neuroinflammatory cytokine release from glial cells, ultimately leading to exacerbation of tau-mediated neurodegeneration.

(C) ApoE regulates the microglial response to amyloid plaques. In the presence of ApoE, phagocytically active disease-associated microglia (DAM) and microglial neurodegenerative phenotype (MGnD) are located near plaques. Tight microglial clustering results in plaque compaction. In the absence of ApoE, periplaque microglia are sparser, and amyloid plaques become larger and less compact. Neuritic dystrophy is significantly increased. On the other hand, if ApoE levels are lower but not absent, neuritic dystrophy is lower.

(D) ApoE may contribute to AD pathophysiology via direct effects on neurons and neuronal network activity. In cell culture, exogenously supplied ApoE4 inhibits neurite outgrowth relative to ApoE3. ApoE4 also contributes to dysfunctional neuronal network activity as evidenced by reduced hilar GABAergic interneurons, increased hippocampal network activity, and a propensity for seizures in ApoE4 target replacement mice.

(E) ApoE4 may directly impair blood-brain barrier (BBB) function in AD by failing to efficiently bind to LRP1 expressed on cells such as pericytes. There is evidence that this leads to increased activation of cyclophilin A signaling pathways and the ultimate breakdown of BBB, resulting in passage of serum proteins (such as fibrin) into the brain parenchyma and eventual neuronal death.

outgrowth, whereas ApoE3 stimulates neurite outgrowth (Holtzman et al., 1995; Nathan et al., 1994). In an ApoE transgenic model, ApoE3 expression in neurons was protective against kainic acid-induced excitotoxic neuronal damage, whereas neuronal ApoE4 expression had no protective effect (Buttini et al., 1999). When ApoE3 and ApoE4 were instead expressed in astrocytes, both isoforms were protective (Buttini et al., 2010). ApoE4-TR adult mice also have lower dendritic spine density and spine length in the cortex (but not the hippocampus)

relative to ApoE2- and ApoE3-TR mice (Dumanis et al., 2009).

ApoE4-TR mice have enhanced neural activity in the hippocampus and entorhinal cortex, as evidenced by hypermetabolism on fMRI, increased high-frequency oscillations measured by *in vivo* electrophysiology, and reduced inhibitory input to neurons of entorhinal cortex (Nuriel et al., 2017). Along these lines, ApoE4-TR adult mice are prone to seizures (Hunter et al., 2012). In cognitively normal human APOE ϵ 4 carriers, there is

increased signal intensity and number of activated regions in the hippocampus on fMRI during memory-activation tasks. These data suggest that ApoE4 may cause neuronal dysfunction via direct neurotoxic effects and by promoting hyperactivity in hippocampal neuronal networks.

Neuronal hyperactivity may be mediated by impaired GABAergic input. GABAergic inhibitory networks are impaired in AD and may contribute to cognitive impairment (Najm et al., 2019). ApoE4-TR mice have decreased numbers of GABAergic interneurons in the hippocampus, and this correlates with learning deficits. When given non-lethal doses of pentobarbital over 4 weeks to boost GABAergic pathways, learning deficits were reduced in ApoE4-TR mice. Pan-neuronal and GABAergic-neuronal conditional ApoE KO in ApoE4-TR mice was protective against neuron loss and memory deficits (Knoferle et al., 2014). Finally, neurons derived from iPSCs from E4/E4 patients as compared to E3/E3 or congenics had higher amounts of hyperphosphorylated tau and reduced GABAergic neurons, effects reduced after treating with a small molecule ApoE structure corrector (Wang et al., 2018).

ApoE4 may also mediate neuropathological effects by directly modulating blood-brain barrier (BBB) integrity (Figure 3E). Studies in the Zlokovic lab have demonstrated that ApoE4 does not efficiently engage LRP1 on pericytes. Lack of ApoE-mediated signaling via this receptor results in activation of proinflammatory cyclophilin-A-NF κ B-MMP-9 signaling cascade. Overactivation of this cascade leads to breakdown of BBB basement membrane and tight junctions, resulting in extravasation of serum proteins (e.g., fibrin) into the brain parenchyma. Exposure to serum proteins can then contribute to neurodegeneration (Bell et al., 2012; Zlokovic, 2013).

Neuroimmune Activation

No area of AD research has experienced more intense investigation in the recent past than the role of the innate immune system in the pathophysiology of AD. Multiple lines of evidence suggest that activation of immune mediators is a critical regulator of AD pathology. Reactive astrogliosis and microgliosis are known to be prominent pathological features in AD brain. Numerous SNPs and rare coding variants in immune-related genes thought to be implicated in microglial function have been identified as risk factors for AD in whole-genome sequencing and GWAS analyses (for review, see Efthymiou and Goate [2017]; Karch and Goate [2015]), including *TREM2*, *CR1*, *SHIP1*, *BIN1*, *CD33*, *PICALM*, *CLU*, and the *MS4A* gene cluster. A non-synonymous coding variant in *PCLG2*, a gene with suspected immune function, has been associated with decreased risk of AD (van der Lee et al., 2019). Of note, many of these immune-related AD risk factor SNPs or coding variants (*ApoE*, *Trem2*, *Cd33*, *Ms4a6d*) have been identified as genes differentially expressed in models of A β deposition as compared to tauopathy, suggesting they may represent amyloid response genes (Matarin et al., 2015). Systems-level analyses of gene regulatory networks in post-mortem human LOAD brain specimens have identified the immune-microglial molecular network as most highly associated with pathophysiology in LOAD (Zhang et al., 2013). A recent, detailed morphological analysis of microglial activation state in brain specimens from two cohorts of cognitive aging found that the proportion of activated microglia (PAM) strongly corre-

lated with the presence of pathologic AD (Felsky et al., 2019). PAM was also strongly associated with the total A β load and number of neuritic plaques and less strongly associated with the amount of PHF tau. Causal mediation modeling generated a model consistent with a proposed pathologic sequence of increased PAM triggering increased PHF tau accumulation, leading to cognitive decline.

Single-cell transcriptomic methods have been employed to identify unique microglial phenotypes associated with A β plaque deposition in animal models of amyloidosis (APP/PS1 and 5XFAD) (Figure 4A). Termed microglial neurodegenerative phenotype (MGnD) or disease-associated microglia (DAM), these cells are defined by a unique expression profile consisting of the upregulation of certain inflammatory transcripts (e.g., *ApoE*, *Trem2*, *Clec7a*) and downregulation of homeostatic transcripts (e.g., *P2ry12*, *Tmem119*). In two studies, these microglia were found to be in close association with neuritic plaques. In one study, MGnD could be induced in wild-type (WT) mouse brain by injection of apoptotic neurons and required ApoE expression for induction (Keren-Shaul et al., 2017; Krasemann et al., 2017). Single-nuclear transcriptomic techniques have recently been applied to human AD brain specimens and have identified microglial subtypes with increased *ApoE* expression but have failed to identify DAM or MGnD subpopulations similar to what has been seen in the mouse brain (Mathys et al., 2019). Further work to better understand similarities and differences between microglia in mouse models versus the human brain are needed.

Disparate Roles of Microglia in AD Pathogenesis. Although microglial activation is associated with disease pathology in AD, it is difficult to parse whether microglial activation in AD is damaging or protective. This may be because of disease-stage-specific effects, with activation being protective in the setting of amyloid deposition (Figure 4B) and damaging in the setting of tau accumulation (Figure 4C).

Phagocytic Microglia Can Limit Amyloid-Associated Pathology. As an example, *TREM2* is an AD risk gene with a rare variant allele, R47H, associated with significantly increased risk of AD (Gratuzi et al., 2018). *TREM2* protein is expressed on microglia, promotes microglial phagocytosis, modulates inflammatory signaling, and promotes microglial survival. *TREM2* also binds to soluble oligomers of A β and promotes phagocytosis of A β . R47H is thought to be a loss-of-function variant (Gratuzi et al., 2018; Shi and Holtzman, 2018). In *TREM2* deletion and haploinsufficiency studies using mouse models of A β deposition (APPPS1-21 and 5xFAD), levels of A β were decreased at 2 months of age (before plaque deposition) but increased at 8.5 months of age (after plaque deposition), suggesting an age- or amyloid-burden effect (Ulrich et al., 2014). Importantly, there was also a reduction in plaque-associated microglia with associated impairments in plaque compaction and increased levels of dystrophic neurites around plaques (Leyns et al., 2017; Song et al., 2018). Either *TREM2* KO or *TREM2* R47H transgene expression in mice that develop amyloid deposition results in enhanced amyloid seeding as well as enhanced tau seeding and spreading near neuritic plaques (Leyns et al., 2019; Parhizkar et al., 2019). This suggests a role of *Trem2* function in suppressing amyloid-induced local toxicity that also




Figure 4. Selected Roles of the Innate Immune System in AD Pathophysiology

(A) Transcriptomic analyses of microglia isolated from mice with amyloid pathology have demonstrated a unique microglial subpopulation (DAM or MGnD) only found in diseased animals, defined by reduced expression of homeostatic genes and increased expression of genes involved in phagocytosis and

inhibits tau seeding and spreading. *CD33* is another AD-susceptibility locus that encodes a transmembrane glycoprotein expressed on the surface of microglia. Increased surface *CD33* expression results in decreased microglial activation. In the J20 amyloid mouse model, *CD33* expression resulted in reduced microglial-mediated phagocytosis of A β and increased amyloid pathology (Bradshaw et al., 2013; Griciuc et al., 2013). *CD33* KO results in decreased amyloid pathology and improved cognition in 5xFAD mice. This is abrogated by additional TREM2 KO; however, *CD33* KO does not reciprocally abrogate effects of TREM2 KO, suggesting that *CD33* acts upstream of TREM2 (Griciuc et al., 2019). Microglia appear to clear A β through a process termed LC3-associated endocytosis (LANDO) that also recycles A β receptors (*CD36*, TREM2, and TLR4) back to the cell surface; if this is genetically deleted in 5xFAD mice, there is increased A β accumulation, microgliosis with release of proinflammatory cytokines, tau hyperphosphorylation, synapse dysfunction, neuron loss, and cognitive impairment (Heckmann et al., 2019). These data in models of A β deposition would suggest that dysfunctional microglia are less able to sequester A β pathology within compact plaques and less able to inhibit amyloid and tau seeding near plaques, resulting in neuronal damage.

Activated Microglia Can Enhance Amyloid Pathology. Alternatively, phagocytosis of A β by microglia can lead to microglial activation. Following phagocytosis by microglia, A β activates the NLRP3 inflammasome, leading to caspase-1 activation and IL-1 β maturation and release (Halle et al., 2008). NLRP3 inflammasome is activated in AD and mild cognitive impairment (MCI) brains and in APPPS1 mice. NLRP3 and caspase-1 genetic deletion results in decreased A β deposition, reduced IL-1 β release from microglia, and improved cognitive performance in APPPS1 mice (Heneka et al., 2013). Following NLRP3 activation, monomers of the apoptosis-associated speck-like protein containing a CARD domain (ASC) can form fibrils and recruit caspase-1, resulting in autoproteolysis and caspase-1 activation as well as leading to further assembly of ASC fibrils into paranuclear specks. Following inflammasome activation, ASC specks can be leaked extracellularly, after which they can be taken up by neighboring microglia to sustain the innate immune response. Extracellular ASC specks have been found to bind to A β and can cross-seed A β oligomerization and plaque formation in APPPS1 mice (Figure 4D). This can be reversed by genetic deletion of ASC or use of an anti-ASC neutralizing antibody (Venegas et al., 2017). In support of a role for microglia in exacerbating amyloid pathology, a recent study using

microglial activation. Expression of ApoE and TREM2 is necessary for the development of this disease-specific subpopulation.

(B) Microglial activation and phagocytosis have disparate effects based on the prominent pathology studied. TREM2 KO results in a microglial phenotype that is less activated and less phagocytic. In mouse models of amyloid deposition, TREM2 KO leads to reduced peri-plaque microglial clustering, increased A β seeding and deposition, and increased dystrophic neurites with enhanced plaque-associated tau pathology.

(C) Conversely, in PS19 tauopathy mice, TREM2 KO leads to reduced neurodegeneration and microgliosis.

(D) A β phagocytosis leads to increased microglial activation. Lysosomal damage by A β can lead to activation of NLRP3 inflammasome, resulting in IL-1 β secretion. Extracellular ASC specks released from activated microglia can then further cross-seed fibrillization of A β into fibrils.

pharmacological depletion of microglia in amyloid mice during the period of plaque deposition demonstrated reduced parenchymal plaques following robust microglial depletion (Spangenberg et al., 2019). Therefore, phagocytosis of A β by microglia may be a double-edged sword: it may serve to limit the spread of amyloid pathology in certain contexts or, alternatively, may promote the spread of amyloid pathology via the mechanisms described above.

Activated Microglia Exacerbate Tau-Associated Pathology. Different results have been observed in models of tau pathology that develop neurodegeneration (Figure 4C). In the PS19 tauopathy mouse, TREM2 deletion significantly reduced tau-mediated neurodegeneration and astrogliosis (Leyns et al., 2017; Sayed et al., 2018). These data would suggest that microglia contribute to neuron death in models of tau-mediated neurodegeneration. Microglial-derived exosomes appear necessary for tau propagation in a model of tau spreading using AAV viral transduced expression of P301Ltau to induce rapid tau spreading from the entorhinal cortex to the dentate gyrus of the hippocampus (Asai et al., 2015). Depletion of microglia or pharmacological inhibition of exosome secretion led to reduced tau spreading in this model.

Direct Microglial Effects on Neuron Viability. Activated microglia can directly secrete toxic proinflammatory cytokines (Colonna and Butovsky, 2017; Kinney et al., 2018) or secrete indirect mediators that stimulate astrocytes to secrete a neurotoxic substance (Liddelow et al., 2017). Microglia may also be directly synaptotoxic. Complement binding (C1q) and microglial phagocytosis lead to early synapse loss in a mouse model with A β plaque deposition (J20 model). C1q binds to synapses and, in the presence of soluble A β oligomers, promotes microglia phagocytosis of synaptic contents (Hong et al., 2016).

Role of Gut Microbiome in Innate Immunity and AD Pathogenesis. There is increasing evidence that interactions between the gut microbiome and the CNS innate immune system (gut-brain axis) may modulate AD pathogenesis. Various aspects of CNS physiology are regulated by the microbiome, including microglial maturation and function (Abdel-Haq et al., 2019). Germ-free mice develop microglia with an immature phenotype, blunted response to inflammatory stimuli, and defective immune response to infection (Erny et al., 2015). The mechanism may involve microbe-derived metabolites. Several studies have profiled the composition of the gut microbiota in both mouse models of amyloidosis (APP/PS1) and in human participants with dementia due to AD and have found significant differences in the overall abundance and diversity of microbial species relative to WT animals or non-demented control participants, respectively (Bäuerl et al., 2018; Saji et al., 2019; Vogt et al., 2017). These alterations may influence microglial responses to disease pathology. Indeed, one study demonstrated that APP/PS1 Δ E9 mice chronically administered a cocktail of high-dose antibiotics to modulate microbiome composition had significantly reduced A β plaque load, reduced plaque size, increased soluble A β 42 levels, and reduced plaque-associated microglia and reactive astrocytes (Minter et al., 2016). Further studies are required to validate these findings, explore the effect of microbiome modulation on other types of AD pathology (e.g., tau), and elucidate underlying mechanisms.

In summary, activation of the innate immune system undoubtedly plays a role in AD pathophysiology. However, data regarding role of activated microglia in animal models suggest possibly divergent effects depending on disease context. Gut microbiota may also modulate the microglial response to pathology. Future studies will need to characterize the expression profiles of microglia from both amyloid- and tau-based animal models using single-cell techniques to determine whether different microglial subpopulations with distinct pathology-associated phenotypes exist. The role of these various microglial-mediated mechanisms in modulating pathology in the human AD brain is unclear and is being actively investigated.

Infectious Hypothesis

Multiple recent studies have revived interest in a long-standing hypothesis that there may be an underlying infectious basis for AD. Dating back to 1991, studies have demonstrated the presence of herpesvirus in brains of patients with AD, as well as within amyloid plaques (Carbone et al., 2014; Jamieson et al., 1991, 1992; Wozniak et al., 2009). A recent systems-level molecular network analysis of preclinical AD brain identified a set of network driver genes noted to be enriched for viral-susceptibility genes. Follow-up analyses in AD brain specimens found detectable human herpesvirus (HHV)-6 and herpes simplex virus (HSV)-1 DNA in three separate cohorts and identified many putative viral-host interactions that regulate gene networks pertinent to AD biology, including innate immunity and APP processing (Readhead et al., 2018).

A β exhibits characteristics of an antimicrobial peptide. Synthetic and AD-brain-derived A β peptide fibrils significantly inhibit the growth of Gram-positive and Gram-negative bacteria, fungus (Soscia et al., 2010), and herpesvirus, while additionally inhibiting the entry of herpesvirus into cells (Bourgade et al., 2015). A β also forms fibrils that entrap bacteria and fungal cells, leading to agglutination *in vitro* (Kumar et al., 2016; Spitzer et al., 2016). The presence of A β in brain parenchyma is linked with protection against infectious bacterial encephalomyelitis experimentally induced by intracerebral inoculation with *Salmonella enterica* typhimurium bacteria in 4-week-old 5xFAD mice. 5xFAD mice survived longer with less severe disease than WT mice, while APP KO mice had slightly increased mortality compared to WT mice. At sites of bacterial deposition in the brain, significant A β deposition was also noted. (Kumar et al., 2016). Similarly, presence of parenchymal A β in 5xFAD mice results in decreased mortality following direct intracerebral HSV inoculation. Areas of brain parenchyma containing deposits of HSV-1 infection also demonstrated increased A β deposition (Eimer et al., 2018).

These experiments have led to the antimicrobial protection hypothesis of AD that suggests intracerebral infection by certain pathogens may induce A β fibrillization as an antimicrobial defense mechanism, leading to amyloid seeding and deposition and thereby initiating the amyloid cascade. (Moir et al., 2018). In support of this theory, HSV-1 viral particles have recently been shown to directly catalyze the fibrillization of A β 42 *in vitro* by nucleating aggregation via contact with the viral surface (Ezzat et al., 2019).

Two recent Taiwanese-based nationwide, matched-control, retrospective cohort studies have evaluated the association of

HSV and varicella zoster virus (VZV) infection with risk of dementia. One study demonstrated a significantly increased risk of developing all-cause dementia (~3-fold increase) in patients greater than 50 years of age following a new HSV infection. This risk was nearly eliminated in patients who received antiherpetic treatment (Tzeng et al., 2018). A second study demonstrated a very slight increased risk of developing all-cause dementia after zoster infection (HR 1.12). Again, a significant decrease in dementia risk was observed in patients that received antiherpetic treatment (HR 0.47) (Chen et al., 2018). The results of these studies will need to be replicated, ideally in a large prospective, longitudinal, observational cohort study, before accepting herpesvirus infection as a bona fide risk factor for AD or related dementias.

Another recent study suggests that periodontal infections may contribute to AD pathogenesis. In this study, periodontal bacterial proteins (gingipains) and DNA were identified in human AD brain. Oral infection of WT mice with *Porphyromonas gingivalis* resulted in elevated intraparenchymal A β levels, and inhibition of gingipain activity led to reduced intracerebral bacterial burden, decreased A β levels, and reduced neuroinflammation (Dominy et al., 2019). Based on these results, a phase 2/3 double-blind, randomized control trial testing use of gingipain inhibitor COR388 is underway in mild-to-moderate AD (ClinicalTrials.gov, ID# NCT03823404).

Sleep

Sleep impairment can lead to impaired attention, concentration, and working memory but may also influence development of underlying AD pathology. Women with sleep-disordered breathing have a higher risk of developing MCI or dementia relative to non-sleep-disordered breathing patients (Yaffe et al., 2011). A single night of sleep deprivation leads to elevated CSF A β 42 levels in healthy middle-aged men (Ooms et al., 2014). Reduced slow-wave sleep in cognitively normal elderly participants is also associated with increased CSF A β 42 (Varga et al., 2016). A study exploring the effect of selective reduction of overnight slow-wave sleep via an automated detection-intervention method in healthy volunteers also demonstrated increased CSF A β levels in participants receiving the study intervention (Ju et al., 2017). However, in a recent study of partial sleep deprivation lasting 5–8 days, no changes in AD CSF biomarkers were noted, although that study did not alter the quantity of slow-wave sleep (Olsson et al., 2018).

In animal microdialysis experiments, interstitial fluid (ISF) A β levels correlate with wakefulness and significantly increase following acute sleep deprivation or orexin infusion. In mice overexpressing A β , acute sleep deprivation caused a significant increase in amyloid plaque deposition. A decrease in amyloid plaque deposition was observed after chronic orexin receptor blockade, resulting in increased sleep (Kang et al., 2009). In mice overexpressing A β , sleep-wake cycle and diurnal fluctuations in ISF and CSF A β levels are normal before an age when animals develop amyloid plaque formation. However, after A β plaque formation, there is an impaired sleep-wake cycle and loss of diurnal fluctuation in ISF or CSF A β levels (Roh et al., 2012). Two main mechanisms have been proposed as to how sleep deprivation or increased wakefulness increases extracellular A β in the brain. Studies from the lab of Maiken Nedergaard

suggest that glymphatic clearance is slower during wakefulness versus sleep (Iliff et al., 2012; Xie et al., 2013). Increased synaptic A β release due to elevated neuronal metabolism and/or activity during wakefulness versus sleep is another mechanism. Increased synaptic and network activity has been previously shown to stimulate release of extracellular A β and tau from neurons (Bero et al., 2011; Brody et al., 2008; Cirrito et al., 2005; Yamada et al., 2014). In a recent study of amyloid kinetics in human CSF using stable isotope labeling, there was an increase in A β levels following sleep deprivation but no change in rate of A β clearance. This suggests the mechanism for increased A β is increased production (Lucey et al., 2018). Similar findings are also noted with extracellular tau. Sleep deprivation in tauopathy mice and healthy human participants resulted in increased ISF or CSF tau levels (Holth et al., 2019). When seeded with recombinant synthetic tau fibrils, sleep-deprived animals had more significant tau spreading relative to non-sleep-deprived animals. In summary, these studies provide compelling evidence that sleep deprivation stimulates increased levels of A β and tau in human CSF and animal model brains and enhances intracerebral pathology.

Therapeutic Strategies for Alzheimer Disease

There are currently four FDA-approved medications for the management of cognitive impairment and dysfunction in global activities in symptomatic AD. These include three cholinesterase inhibitors (ChEIs; donepezil, rivastigmine, and galantamine) and memantine, an uncompetitive NMDA receptor modulator. Despite enormous efforts by the pharmaceutical industry, there remains no effective disease-modifying therapy available today. More than 20 compounds have completed large phase 3, double-blind, randomized control trials in cohorts of patients at various stages of AD, and none has demonstrated any efficacy in slowing cognitive decline or improving global functioning (Table 1). These many trial failures highlight the need for different approaches to clinical trial design in AD.

First, most of the failed phase 3 trials intervened on patients with mild-to-moderate symptomatic AD. Though this represents an intermediate phase of clinical disease, this is actually an advanced stage of the biological disease when considering that pathology accumulates in the AD brain 15–20 years prior to onset of clinical symptoms (Vermunt et al., 2019). At this stage of disease pathogenesis, significant and irreversible synaptic and neuronal loss has occurred, and the pathological cascade would likely be very difficult to reverse (Gómez-Isla et al., 1996). Instead, disease-modifying clinical interventions applied as early in the preclinical phase of disease as possible in a preventative study design might have a better chance of changing disease trajectory before the onset of frank neurodegeneration. Several recent large-scale clinical trials have adopted a secondary or primary prevention paradigm: the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) drawing from the large DIAN cohort of ADAD patients (Bateman et al., 2017), the A4 trial enrolling participants with confirmed preclinical AD by biomarker assessment (Sperling et al., 2014), and the Alzheimer Prevention Initiative (API) using a cohort of patients with ADAD as well as a separate cohort of older homozygous APOE ϵ 4/ ϵ 4 carriers (Reiman et al., 2011). Importantly, each study is testing

Table 1. Discontinued Phase 3 Disease-Modifying Drug Trials in AD, Excluding ChEI and Memantine Trials

Drug (Study Name)	Study Population	Target/Mechanism	Type of Molecule	Outcome	ClinicalTrials.gov NCT Identifier	Reference
Bapinezumab	Mild-to-moderate AD	Soluble and fibrillar A β	Monoclonal antibody	No effect on cognition or ADL	NCT00575055 NCT00574132	(Salloway et al., 2014)
Solanezumab (EXPEDITION-1, 2 and 3)	Mild-to-moderate AD; mild AD	Soluble monomeric A β	Monoclonal antibody	No effect on cognition or ADL	NCT00905372 NCT00904683	(Doody et al., 2014; Honig et al., 2018)
Crenezumab (CREAD-1/2)	very-mild-to-mild AD with amyloid positive biomarkers	Oligomeric, fibrillar and plaque-based A β	Monoclonal antibody	No effect on cognition or ADL on preliminary analysis	NCT03114657	
Aducanumab (ENGAGE; EMERGE)	Mild AD	Conformation-specific A β aggregates	Monoclonal Antibody	No change in rate of cognitive decline	NCT03639987	(Selkoe, 2019)
AN-1792	Mild-to-moderate AD	Active immunization	Full-length A β 42 immunogen	Trial halted due to development of meningoencephalitis in 4 patients	NCT00021723	
Semagacestat (IDENTITY-1/2)	Mild-to-moderate AD	γ -secretase inhibitor	Small molecule	No effect on cognition or ADL; increased risk of skin cancer	NCT01035138 NCT00594568	(Doody et al., 2013)
Tarenflurbil	Mild AD	γ -secretase modulator	Small molecule	No effect on cognition or ADL	NCT00105547	(Green et al., 2009)
CNP520 (Umibecestat) (API Generation)	Cognitively normal APOE ϵ 4/ ϵ 4 carriers	BACE1 inhibitor	Small molecule	Worse cognitive performance, weight loss	NCT03131453 NCT02565511	(Lopez Lopez et al., 2019)
Lanabecestat (AMARANTH; DAYBREAK-ALZ)	Very-mild-to-mild AD	BACE1 inhibitor	Small molecule	No effect on cognition or ADL	NCT02783573 NCT02245737	
Atabecestat	Preclinical AD; positive amyloid, normal cognition	BACE1 inhibitor	Small molecule	Worse performance on some cognitive tests; in some cases, prominent side effects	NCT02569398	(Henley et al., 2019)
Verubecestat (APECS)	Prodromal AD	BACE1 inhibitor	Small molecule	Worse performance on some cognitive tests and in ADL	NCT01953601	(Egan et al., 2018, 2019)
Elenbecestat (MISSION-AD1/2)	Mild AD	BACE1 inhibitor	Small molecule	Unspecified safety concerns upon interim review	NCT02956486 NCT03036280	
Intepirdine	Mild-to-moderate AD	5-HT $_6$ receptor antagonist	Small molecule	No effect on cognition or ADL	NCT02585934	
Idalopirdine (STARBEAM)	Mild-to-moderate AD	5-HT $_6$ receptor antagonist	Small molecule	No effect on cognition or ADL	NCT02006641	(Atri et al., 2018)
Dimebon	Mild-to-moderate AD	Pleiotropic: anti-histamine, mitochondria, others	Small molecule	No effect on cognition or ADL	NCT00675623	(Cano-Cuenca et al., 2014)
Nilvadipine	Mild-to-moderate AD	Calcium channel blocker	Small molecule	No effect on cognition or ADL	NCT02017340	(Lawlor et al., 2018)
Naproxen, celecoxib (ADAPT study)	Prevention study; Cognitively normal elderly with parent or sibling with dementia	Anti-inflammatory; COX inhibitor (NSAID)	Small molecule	No delay in time to incident cognitive impairment after 1–3 years treatment and 7 years follow-up	NCT00007189	(ADAPT-FS Research Group, 2015)
Indomethacin	Mild-to-moderate AD	Anti-inflammatory; COX inhibitor (NSAID)	Small molecule	No effect after 1 year treatment on cognition or ADL; study under-powered	NCT00432081	(de Jong et al., 2008)

(Continued on next page)

Table 1. Continued

Drug (Study Name)	Study Population	Target/Mechanism	Type of Molecule	Outcome	ClinicalTrials.gov NCT Identifier	Reference
Prednisone	Mild-to-moderate AD	Anti-inflammatory	Small molecule	No effect on cognition or ADL	NCT00000178	(Aisen et al., 2000)
Intravenous immunoglobulin (IVIg)	Mild-to-moderate AD	Immunomodulator	Pooled Ig	No effect on cognition or ADL	NCT00818662	(Relkin et al., 2017)
LMTM	Very-mild-to-mild AD	Tau aggregation inhibitor; methylene blue derivative	Small molecule	No effect on cognition or ADL	NCT01689233	(Gauthier et al., 2016)
Simvastatin (CLASP and ESPRIT studies)	Mild-to-moderate AD	HMGCoA-reductase inhibitor; cholesterol lowering agent	Small molecule	Some improvement on a few cognitive tests but no effect on ADL	NCT00053599 NCT00486044	(Carlsson et al., 2008; Sano et al., 2011)
Atorvastatin	Mild-to-moderate AD	HMGCoA-reductase inhibitor; cholesterol-lowering agent	Small molecule	No effect on cognition or ADL	NCT00151502	(Feldman et al., 2010)
Rosiglitazone (REFLECT-2/3)	Mild-to-moderate AD	PPAR γ agonist	Small molecule	No effect on cognition or ADL	NCT00594568 NCT00428090	(Harrington et al., 2011)
Tricaprilin	Mild-to-moderate AD	Improve mitochondrial metabolism	Small molecule	No effect on cognition or ADL	NCT01741194	

anti-amyloid therapies in cognitively normal patients who are at high risk for developing the disease.

Second, it is important to reconsider assumptions and underlying hypotheses with regard to disease pathogenesis. While the underlying evidence for the amyloid cascade hypothesis remains solid, new discoveries should continually inform and update our understanding of disease pathobiology, eventually leading to the development of novel treatment approaches.

The current AD clinical pipeline has over 100 different compounds being tested in various phases of clinical trials (Hara et al., 2019). We will now review available symptomatic treatments and developments on the path to identifying disease-modifying therapies.

Symptomatic Treatment

Cholinesterase Inhibitors

During the course of AD pathogenesis, cholinergic neurons in the nucleus basalis of Meynert and other septal nuclei that project widely throughout the cortex are lost, causing a general cholinergic deficit (Bartus et al., 1982). This loss of cholinergic input is thought to contribute to early attention and memory dysfunction in AD. ChEIs work to reverse this deficiency by increasing synaptic levels of acetylcholine. Three ChEIs are currently approved for use in mild-to-moderate AD: donepezil, rivastigmine, and galantamine. They differ primarily in their pharmacokinetic profiles (donepezil has a much longer half-life than the others and is dosed once daily) and formulation (rivastigmine is available as a continuous-release transdermal patch) but not in overall efficacy. Their symptomatic benefit in AD has been confirmed via meta-analyses assessing both cognitive performance and global functioning (Birks, 2006). However, the overall effect size is modest (mean difference in Mini-Mental State

Examination [MMSE] of 1.37 points after 6 months treatment), and there is no effect on long-term disease progression. Available data do not support the use of ChEIs in very mild AD (i.e., mild cognitive impairment), and in fact, ChEI may worsen cognition at this early clinical stage (Han et al., 2019).

Anti-NMDA

Memantine is an uncompetitive NMDA receptor modulator that may act to inhibit glutamate-mediated neurotoxicity that develops as neurons die during AD progression, although the precise mechanism of its effect is unclear (Greenamyre et al., 1988; Livingston et al., 2017). Meta-analysis confirms the efficacy of memantine in moderate-to-severe AD on measures of cognition, activities of daily living (ADL), and neuropsychiatric symptoms (McShane et al., 2006). However, as with ChEI, the effect size is quite small, and the medication has no effect on long-term disease progression. Effects in mild-to-moderate stage disease were marginal, and therefore, it is not recommended that this medication be prescribed to patients with mild AD.

Disease-Modifying Treatments

A β -Directed Therapeutics

The goal of many A β -directed therapies is to lower levels of parenchymal A β and amyloid deposits in the AD brain. The amyloid cascade hypothesis suggests that A β accumulation triggers disease pathogenesis, so therapies that lower parenchymal A β might be expected to slow disease progression. Since no integrated AD animal model exists in which to definitively test the validity of the amyloid cascade hypothesis, clinical trials using A β -directed therapies in humans have been considered one of the most direct ways to test this. Unfortunately, many clinical trials have been inadequately designed to robustly test the amyloid hypothesis, such that negative trial results cannot be necessarily

Table 2. Active Phase 3 Disease-Modifying Drug Trials in AD

Drug	Study Population	Target	Type of Molecule	Status	ClinicalTrials.gov NCT Identifier
Gantenerumab	Very-mild-to-mild AD	Conformational epitope found only on fibrillar AD	Monoclonal antibody	Phase 3 enrolling	NCT03444870
BAN2401 (CLARITY)	Very-mild-to-mild AD with positive amyloid biomarkers	A β protofibrils	Monoclonal antibody	Phase 3 enrolling	NCT03887455
ALZT-OP1 (cromolyn sodium/ibuprofen)	Very mild AD with positive CSF amyloid	Anti-inflammatory	Small molecule	Phase 3 enrolling	NCT02547818
Levetiracetam	Very mild AD with positive amyloid PET imaging	SV2A	Small molecule	Phase 3 enrolling	NCT03486938
CAD106	Cognitively normal ApoE ϵ 4/ ϵ 4 homozygotes	Active immunization with A β 1-6 peptide fused to virus-like particles	Immunogen	Phase 3 no longer enrolling; API Generation primary prevention study	NCT02565511
COR388	Mild-to-moderate AD	Periodontal bacteria gingipain inhibitor	Small molecule	Phase 3 enrolling	NCT03823404
ANAVEX 2-73	Very-early-to-mild AD with positive amyloid biomarkers	Sigma-1 protein agonist	Small molecule	Phase 3 enrolling	NCT03790709

interpreted as a rejection of the amyloid hypothesis (Karran and Hardy, 2014; Karran et al., 2011). Active and passive immunization strategies and use of secretase inhibitors have been the primary modes of targeting A β in clinical trials.

Active Immunization. A β -directed immunotherapy has been explored as a disease-modifying therapy in AD for the last 20 years (Gallardo and Holtzman, 2017). The first successful demonstration of antibody-mediated clearance of A β was in 1999, when active immunization of PDAPP mice using full-length human A β 42 peptide resulted in a significant decrease in existing amyloid deposits in animals vaccinated at an older age and almost completely prevented the development of amyloid deposition in animals vaccinated at a younger age (Schenk et al., 1999). This subsequently led to the development of the first human A β immunotherapy trial using AN-1792, a mixture of synthetic full-length human A β 42 with adjuvant. In a phase 2a trial, four patients developed aseptic meningoencephalitis, leading to the discontinuation of the trial, although ongoing neuroimaging and neuropathologic follow-up allowed for assessment of long-term treatment response. 25 of 129 patients were deemed to be antibody responders. Post-mortem evaluation determined that there was significant variability in degree of amyloid clearance but that some vaccinated patients had long-lasting, nearly complete clearance of A β deposits. However, they still had prominent tau pathology with advanced Braak staging, and most had severe dementia at time of death, even despite plaque clearance (Nicoll et al., 2019; Vellas et al., 2009). Active vaccination strategies using A β peptides as immunogens are still being pursued, with CAD106 in a phase 3 trial (Table 2) and ABVac40 currently in phase 2 trials (Lacosta et al., 2018; Vandenbergh et al., 2016). Both claim to avoid the risk of meningoencephalitis by excluding portions of the A β peptide responsible for inducing Th1 immune responses.

Passive Immunization. Passive immunotherapy is another strategy for immunologically targeting A β clearance. With infusions of a monoclonal antibody, there is less variability in efficacy from patient to patient, and since titer levels can be more tightly controlled, there is less risk of adverse events. Six

different monoclonal antibodies directed against A β have advanced to phase 3 clinical trials. The first monoclonal antibody to do so was bapinezumab. This is a humanized version of mouse 3D6 antibody that targets N-terminal A β peptide and binds to soluble and fibrillar A β , triggering microglial phagocytosis of A β deposits. This antibody was tested in two parallel phase 3 trials in mild-to-moderate AD patients and had no effect on cognition or ADL at the doses tested (Salloway et al., 2014). In high concentrations, it was associated with amyloid-related imaging abnormalities (ARIA) edema and microhemorrhages. Solanezumab is a humanized version of mouse antibody m226 whose epitope lies within the A β mid-domain and binds only to soluble A β , not fibrillar or plaque-based A β . Preclinical studies demonstrated that peripheral administration sequestered peripheral A β and led to a dramatic and rapid rise in peripheral A β levels. It was hypothesized that the antibody might alter the equilibrium between plasma and CNS A β , the so-called peripheral sink hypothesis (DeMattos et al., 2001), as well as directly binding soluble A β in the CNS. Two phase 3 trials of solanezumab in mild-to-moderate AD failed to demonstrate a marked benefit on cognition or ADL and did not reduce cerebral amyloid deposition (Doody et al., 2014). A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018). Aducanumab is a fully human IgG1 antibody that binds a specific conformational epitope of A β . There was initial excitement for this antibody, as it was demonstrated to actively engage and clear amyloid plaques both in transgenic APP models and in human participants with prodromal or mild AD based on florbetapir-PET imaging. Further, after 1 year of monthly infusions, participants receiving aducanumab had slower decline in CDR-sum of boxes and MMSE in a phase 1b trial (Sevigny et al., 2016). Unfortunately, two phase 3 trials in mild AD were stopped early for futility in March 2019, after interim analysis suggested no change in cognitive decline (Selkoe, 2019). Crenezumab is a fully human IgG4 antibody that binds oligomeric, fibrillar, and plaque-based A β . Two phase 3 trials were terminated early in January 2019 for futility after interim analysis failed to demonstrate any benefit. Gantenerumab is a

fully human IgG1 antibody that binds to a conformational epitope on aggregated A β fibrils within plaques and triggers Fc-mediated microglial phagocytosis of A β . Gantenerumab entered a phase 3 clinical trial for mild AD in 2014 that ultimately stopped enrolling early due to futility. The study was continued as an open label extension at high dose for 2 years. Follow-up analyses demonstrated a dramatic decline in A β deposition in participants in the open extension, such that some became amyloid negative on imaging. Based on this, a new high-dose phase 3 trial has been initiated in very-mild-to-mild AD (Ostrowitzki et al., 2017). BAN2401 is a humanized version of murine antibody mAb158 that binds large soluble A β protofibrils *in vitro*. Phase 2 trials demonstrated significant engagement and clearance of cerebral amyloid deposits and possible reduction in cognitive decline. It has now entered a phase 3 clinical trial in very-mild-to-mild AD patients (Logovinsky et al., 2016). Donanemab, a monoclonal antibody developed by Lilly that uniquely targets A β (p3-42) (a pyroglutamate form of A β exclusively found in plaques) in which the goal is to directly engage plaque-based A β for clearance, is currently in a phase 2 trial.

Though the data for A β -directed monoclonal antibodies in symptomatic AD have been discouraging, several antibodies are currently being used in primary and secondary prevention studies where dose administration at an earlier disease stage might provide a better opportunity for disease modification. DIAN-TU is using solanezumab and gantenerumab in a phase 2/3 adaptive design clinical trial in ADAD mutation carriers known to inevitably develop disease (Bateman et al., 2017). Crenezumab is being used in the API ADAD Colombia trial of known mutation carriers (Tariot et al., 2018), whereas active immunization with CAD106 is being used in the API Generation trial of APOE ϵ 4 homozygotes (Lopez Lopez et al., 2019).

Secretase Inhibitors. An alternative strategy for reducing A β levels is to reduce production via inhibition of β - and γ -secretase activities. The rate-limiting step for A β production is enzymatic cleavage by BACE1, so this would seem to be a particularly attractive target. In mouse amyloidosis model, BACE1 inhibition limits initiation of new plaque formation but does not prevent growth of established plaques (Peters et al., 2018). Thus, BACE1 inhibition might be expected to work synergistically in combination with A β -directed monoclonal antibodies to reduce A β deposition by addressing both clearance and production of A β . Ideally, BACE1 inhibition would be the preferred target for primary prevention studies, as blocking A β production prior to onset of pathology would be sufficient to prevent the development of pathology. The reality of BACE1 inhibitors in clinical testing has been more challenging.

A number of BACE1 inhibitors have entered clinical trials in recent years. Lilly inhibitors LY2886721 and LY3202626 failed in phase 2 trials due to hepatotoxicity and impaired cognitive performance, respectively. Five additional BACE1 inhibitors have now failed phase 3 clinical trials due to lack of efficacy and/or associated side effects (Table 1). Verubecestat failed to slow cognitive decline in a phase 3 trial of mild-to-moderate AD and resulted in worse cognition on some measures. (Egan et al., 2018, 2019). Lanabacestat was discontinued after interim analysis in biomarker-confirmed very-mild-to-mild AD failed to detect any reduction in cognitive decline, despite evidence of

target engagement (Clinicaltrials.gov, ID# NCT#02783573). Atabecestat was discontinued after a trial in preclinical AD demonstrated frequent hepatotoxicity and worse cognitive outcomes than placebo (Henley et al., 2019). CNP520 (umibecestat) was initially found to be safe and well tolerated in early phase 1 and 2a studies. This inhibitor was then incorporated into one arm of the phase 2/3 API Generation study (along with CAD106; see above) for secondary prevention of AD in older APOE ϵ 4/ ϵ 4 homozygotes (Lopez Lopez et al., 2019). Unfortunately, study sponsors announced discontinuation of this arm in July 2019, when interim analysis demonstrated worse cognition, increased brain atrophy, and more weight loss in the treatment group relative to placebo. Only one BACE1 inhibitor, elenbecestat, was left standing in clinical trials until September 2019, when study sponsors announced discontinuation of ongoing clinical trials in biomarker-positive MCI and/or prodromal AD after review of interim safety data. The Alzheimer's Clinical Trials Consortium had planned to use elenbecestat in upcoming primary and secondary prevention studies but now will proceed only with BAN2401 (Panza et al., 2018). At this point, no additional BACE1 inhibitors are being actively investigated in clinical trials.

At this point, it appears that worsening cognitive function and weight loss are possible class effects for BACE1 inhibitors, as they were observed as adverse effects across multiple trials. These may not be simply off-target effects. BACE1 has substrates other than APP that are likely important in neurodevelopment, as evidenced by the fact that BACE1 KO mice develop seizures (Hitt et al., 2010), myelination deficits (Willem et al., 2006), cognitive impairment (Laird et al., 2005), and axon guidance defects (Rajapaksha et al., 2011). Conditional BACE1 KO in adulthood mitigates many of these side effects, but there remain impaired axon guidance defects (Ou-Yang et al., 2018). Based on these data, it may be difficult to develop a BACE1 inhibitor without some expected on-target side effects.

Two γ -secretase inhibitors (GSIs) have been tested clinically as disease-modifying therapies for AD, and each have failed due to lack of efficacy or worsening of cognition combined with dose-limiting adverse side effects. Avagacestat phase 2 trials in mild-to-moderate and prodromal AD were terminated after it failed to demonstrate any reduction in cognitive decline and caused adverse effects at higher doses, such as nausea, vomiting, diarrhea, rash, pruritis, and increased incidence of non-melanoma skin cancer (Coric et al., 2015). Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013). Likely the broad-spectrum nature of these GSIs contributed to their side-effect profile, as Notch signaling and downstream pathways from other substrates would be inhibited (De Strooper, 2014). Alternatively, side effects might be attributable to on-target inhibition of APP processing, resulting in accumulating levels of membrane-bound N-terminally cleaved APP fragments. The same concern might also apply to BACE1 inhibitors.

An alternative means of inhibiting amyloidogenic processing of A β by γ -secretase is to use γ -secretase modulators (GSMs) that

alter processing of APP (lower A β 42 and higher A β 40 levels) without influencing processing of other substrates (Xia, 2019). The mechanism appears to be related to slowed dissociation of ϵ -cleaved C99 fragment, thereby increasing enzyme processivity and leading to generation of shorter A β fragments (Okochi et al., 2013). The first GSMs were discovered by recognizing that ibuprofen, indomethacin, and sulindac reduce A β 42 levels (Weggen et al., 2001) through modulation of γ -secretase activity (Eriksen et al., 2003). This eventually led to identification of R-flurbiprofen (tarenflurbil), a molecule having GSM activity but without inhibitory effects on cyclooxygenase activity. Despite promising preclinical data, unfortunately, a phase 3 clinical trial did not demonstrate any benefits on cognition or ADLs over the course of 18 months (Green et al., 2009). However, significant CNS A β 42 lowering was not likely achieved (Karran and Hardy, 2014); therefore, more efficacious GSMs may still be a viable conceptual approach. Indeed, there are other promising GSMs now in development that may enter human trials in the near future (Wagner et al., 2017). With the recent publication of high-resolution substrate-enzyme cryo-EM structures for γ -secretase-APP C83 fragment and γ -secretase-Notch 100 fragment (Yang et al., 2019; Zhou et al., 2019), it may now be possible to more easily develop substrate-specific γ -secretase inhibitors or modulators.

Tau-Directed Therapeutics

Tau is considered a critical target for developing disease-modifying therapies. Multiple strategies have been proposed for reducing tau pathogenicity in AD. One of the first compounds tested in a clinical trial was methylene blue. Any putative benefit attributed to methylene blue has been thought to be secondary to reduced tau fibrillization and aggregation and induction of autophagy, which leads to reduced tau pathology and neuron death in mouse models of tauopathy (Congdon et al., 2012; Crowe et al., 2013; Wischik et al., 1996). A second-generation stabilized and reduced derivative of methylene blue called LMTM was created and moved to clinical trials. Unfortunately, in two different phase 3 trials testing LMTM in all-cause dementia and mild-to-moderate AD, there was no reduction in rate of decline of cognition or ADL compared to placebo (Gauthier et al., 2016). Whether LMTM at the doses administered prevented accumulation of aggregated tau or decreased existing deposits was not tested.

A second strategy for reducing tau pathogenicity is to inhibit abnormal hyperphosphorylation through use of tau kinase inhibitors. A GSK-3 inhibitor, tideglusib, was shown in a preclinical study using double transgenic mice expressing human tau and APP to reduce tau phosphorylation, decrease amyloid deposition, lead to less neuronal loss, and improve cognition (Serenó et al., 2009). However, a phase 2 trial in mild-to-moderate AD did not demonstrate any reduction in rate of cognitive or functional decline as compared to placebo (Lovestone et al., 2015).

As with A β , a significant amount of investment has been made in developing immunotherapies to facilitate tau pathology clearance from the brain, including both active and passive immunization. Two active immunization strategies are being investigated. AADvac-1 consists of tau peptide containing amino acids 294–305 conjugated to keyhole limpet hemocyanin with use of adjuvant. AADvac-1 recently completed phase

1 testing and is currently undergoing phase 2 trials (Novak et al., 2019). ACI-35 is another active vaccination attempt using 16 copies of synthetic phosphorylated tau fragment embedded in liposome. The goal is to generate an immune response against pathologic phosphorylated tau with no cross-reactivity against non-pathologic tau. This has completed phase 1 clinical testing and awaits further phase 2 testing in the future.

Numerous tau-directed monoclonal antibodies have been generated and are currently being tested in clinical trials. In preclinical studies, mouse anti-human tau monoclonal antibody HJ8.5 demonstrated reduced tau seeding, hyperphosphorylation and thioflavin S staining, reduced levels of detergent insoluble tau, and reduced brain atrophy and cognitive deficits in PS19 (P301S) mice—whether administered via intraventricular infusion (Yanamandra et al., 2013) or peripherally (Yanamandra et al., 2015) prior to the development of significant tau pathology. This antibody has been humanized and, in a single patient with progressive supranuclear palsy (PSP), led to increased plasma tau concentrations after intravenous injection. In PS19 mice, plasma tau was found to inversely correlate with brain soluble tau levels, suggesting that peripheral tau levels reflect changes occurring in the CNS (Yanamandra et al., 2017). The humanized version of HJ8.5 (ABV-8E12) has been tested in a phase 1 trial and found to be safe; ABV-8E12 has now advanced to two phase 2 trials including patients with early AD and PSP (West et al., 2017). The PSP study was just terminated following a futility analysis. A separate Biogen humanized anti-tau monoclonal antibody (BIB092) has also been tested in phase 1 study in PSP patients, passed safety parameters, and was demonstrated to reduce N-terminal tau in CSF of patients. This antibody has now advanced to phase 2 testing in PSP and AD (Boxer et al., 2019). Biogen and other companies have additional monoclonal antibodies targeting tau that are in the clinical pipeline: R07105705, BIB076, JNJ-63733657, LY3303560, MC1-L, and UCB1017. A critical issue is to determine the extent to which pathological seeding and spreading of tau pathology occurs via extracellular forms of tau and whether such a mechanism occurs in humans. It is likely that if a peripherally administered anti-tau antibody is to be efficacious in a disease such as AD, such a mechanism would need to occur, and an antibody would need to inhibit this process. If antibody-based methods are developed to degrade and reduce intracellular, cytoplasmic forms of tau, this may prove to be a more effective way to not only prevent but also clear existing tau pathology.

Finally, a separate strategy to limit tau-mediated pathology would be to reduce tau expression. One clinically viable approach is the use of intrathecally delivered ASOs. ASO-based clinical treatments have demonstrated dramatic success in cases of spinal motor atrophy (Finkel et al., 2017) and are being tested in Huntington's disease (Tabrizi et al., 2019). Preclinical studies using tau-overexpressing mice suggest this approach may be viable in tauopathies (DeVos et al., 2017). Ionis has initiated a phase 1/2 trial of anti-tau ASOs (MAPTRx) in mild AD (Clinictrials.gov, ID# NCT03186989).

ApoE-Directed Therapeutics

To date, no in-human AD clinical trials have targeted ApoE. However, a number of preclinical studies in relevant animal

models have investigated ApoE-directed therapies that may eventually translate clinically.

Multiple studies employing ApoE genetic deletion (Bales et al., 1999; Verghese et al., 2013), conditional expression of ApoE isoforms (Liu et al., 2017), or ASO-mediated knockdown of ApoE expression (Huynh et al., 2017b) suggest that lowering ApoE levels reduces relevant pathology in both amyloidosis and tauopathy mouse models (Shi et al., 2017). Use of anti-ApoE ASO delivered via intracerebroventricular injection in ApoE-TR/APPSP1-21 mice demonstrated dramatically reduced A β plaque deposition if administered prior to plaque seeding but not after. Neuritic dystrophy was also significantly attenuated, independent of an effect on amyloid deposition even when administered after amyloid deposition (Huynh et al., 2017b). Therefore, targeting ApoE3 or ApoE4 expression via ASO delivery in AD may be beneficial, especially if administered in early preclinical phases. Since ApoE promotes plaque-associated microgliosis resulting in plaque compaction and reduced neuritic dystrophy (Ulrich et al., 2018), therapeutically reducing ApoE levels may also have unexpected effects on the innate immune response to established plaques. An alternative strategy for lowering A β levels via targeting a certain form of ApoE is the use of passive immunization. Monoclonal antibody HJ6.3 delivered peripherally to APP/PS1 mice either before or after plaque deposition resulted in reduced A β levels and fibrillary amyloid pathology, increased microglial activation, and improved spatial-memory performance (Kim et al., 2012; Liao et al., 2014). HAE-4 is a monoclonal antibody that targets non-lipidated, aggregated ApoE3 and E4 preferentially located within amyloid plaques. Delivery of this antibody centrally or peripherally reduced fibrillary amyloid plaque load along with soluble and insoluble A β levels without reducing cerebral or plasma ApoE levels. Instead, data suggest the antibody mediates its effect by binding apoE in plaques followed by antibody-mediated plaque opsonization by microglia, likely promoting peri-plaque A β phagocytosis (Liao et al., 2018).

Another proposed strategy is to utilize gene-therapy methods to overexpress ApoE2 in *APOE* $\epsilon 4/\epsilon 4$ carriers as a means to overcome loss of function associated with ApoE4 (Rosenberg et al., 2018). This strategy would only be effective if ApoE4-mediated disease mechanisms are truly due to loss of function or, if secondary to ApoE4 toxic gain of function, if ApoE2 is able to act in dominant protective fashion to inhibit ApoE4 toxic effects. While there are data to support the concept that ApoE2 expression may be protective using a gene-transfer approach (Hu et al., 2015; Hudry et al., 2013), it would be useful to validate protective effects and lack of toxicity in a number of different models. ApoE modulates AD pathobiology through various pathways (see above), so it will be important to confirm that *APOE2* overexpression has only salutary effects on these many disease-relevant biological functions. This is especially critical after a recent study in the preclinical literature demonstrated that *APOE2* expression via viral delivery exacerbated pathology in tauopathy mice (Zhao et al., 2018). It is unclear whether ApoE2 gene delivery would be a superior strategy to simply lowering ApoE levels (discussed above). A recent study tested *APOE2* gene delivery in non-human primates using AAVrh.10 hAPOE2-HA vector to deliver an *APOE2* expression cassette.

This study found that intracisternal viral injection led to the widest area of cerebral transduction with only minimal surgery (Rosenberg et al., 2018). A phase 1 clinical trial in humans using intracisternal injection of this vector is planned (ClinicalTrials.gov, ID# NCT03634007).

Immune Modulation

Interest in anti-inflammatory treatments for AD were initially stoked by findings from multiple epidemiologic studies suggesting that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with lower incidence of AD, with the most pronounced effect seen in patients taking chronic ibuprofen (in t' Veld et al., 2001; Vlad et al., 2008). However, follow-up clinical trials testing the effect of low-dose prednisone (Aisen et al., 2000), low-dose aspirin (AD2000 Collaborative Group et al., 2008), NSAIDs (Aisen et al., 2003; de Jong et al., 2008), and selective COX-2 inhibitors (Aisen et al., 2003; Thal et al., 2005) failed to show any reduction in rate of cognitive decline in mild-to-moderate AD. Prevention studies of naproxen and celecoxib in patients at risk for preclinical AD also failed to demonstrate any protective benefit (ADAPT-FS Research Group, 2015; Meyer et al., 2019). Therefore, a generic anti-inflammatory treatment approach for AD does not appear viable for secondary prevention or treatment of symptomatic patients.

In one study, patients with rheumatoid arthritis treated with etanercept, TNF α decoy receptor, had lower incidence of AD, but no effect was noted with use of other anti-rheumatic medications (e.g., prednisone, sulfasalazine, and rituximab) or anti-TNF agents (e.g., infliximab and adalimumab) (Chou et al., 2016). A phase 2 trial of etanercept in mild-to-moderate AD established safety but saw no significant reduction in cognitive decline on analysis of secondary clinical outcomes (Butchart et al., 2015). It is notable that etanercept does not cross the BBB. One strategy to enhance etanercept delivery across the BBB is by fusing the molecule to transferrin receptor. This approach demonstrated reduced amyloid burden and improvement in recognition memory in preclinical studies using APP/PS1 mice (Chang et al., 2017). Preclinical models have demonstrated protection from synaptic deficits in rodent amyloidosis models following treatment with inflammasome inhibitors before onset of amyloid plaques (Qi et al., 2018).

Intravenous immunoglobulin (IVIg) is an immunomodulatory treatment approved for treatment of various neurologic and rheumatologic autoimmune diseases. However, a phase 3 trial of IVIg did not demonstrate any cognitive benefits in mild AD despite a favorable safety profile (Relkin et al., 2017).

A separate treatment approach is to boost microglial activation or phagocytic function, since several AD gene risk variants in *TREM2* and *CD33* act to decrease microglial activation and phagocytosis (see above). *TREM2*-activating monoclonal antibodies have entered phase I clinical trials (ClinicalTrials.gov, ID# NCT03635047). *CD33*-blocking antibodies are also being planned for phase 1 clinical trials (ClinicalTrials.gov, ID# NCT03822208).

Young Blood

Recent heterochronic parabiosis experiments demonstrated that introduction of young blood in old mice led to increased neurogenesis and dendritic spine density and improved age-related cognitive impairment (Katsimpardi et al., 2014; Villeda et al.,

2014). This effect was also seen after injection of human umbilical cord blood (Castellano et al., 2017). Serum from young mice promoted increased numbers of functional synapses, increased dendritic arborization, increased synaptic response to stimuli, and increased NMDA synaptic responses in co-cultures of human neurons with mouse glia. Such effects were not seen with serum from old mice or fetal bovine serum (FBS). Proteomic and functional validation experiments suggest that the effect is at least partly mediated by SPARC1L and thrombospondin-4 (Gan and Südhof, 2019). Heterochronic parabiosis and direct injection of young mouse plasma in APP amyloidosis mice resulted in increased levels of synaptic protein and improvement in cognitive performance on standard tests of spatial working memory and hippocampal-dependent associative learning (Middeldorp et al., 2016).

These studies have led to increased off-label clinical administration of young-donor plasma to individuals for a list of age-related conditions, leading the FDA to release a statement recommending against this given the lack of current evidence to support the practice (Commissioner, 2019).

This approach is being tested currently in clinical trials. A completed phase 1 trial of weekly infusions of 1 unit of young fresh, frozen plasma from male donors (aged 18–30) versus saline in patients with mild-to-moderate AD for a total of 4 weeks demonstrated that the intervention was mostly well tolerated (Sha et al., 2019). A concentrated plasma fraction derived from young-donor plasma is now being tested in a phase 2 trial (Kheifets and Braithwaite, 2019). Plasma exchange may work to simply remove detrimental plasma components from old blood or mobilize CSF A β rather than supply therapeutic factors from young blood. The AMBAR trial, a current phase 2b/3 trial, is testing this hypothesis by assessing the effect of monthly plasma exchange with albumin replacement on mild-to-moderate AD (Boada et al., 2019).

Combination Therapies

Using the example of treatment paradigms for other chronic diseases, such as hypertension, congestive heart failure, epilepsy, HIV, and others, a combinatorial treatment strategy for AD seems more likely to yield clinical successes than monotherapy (Gauthier et al., 2019; Morris, 2019; Stephenson et al., 2015). Many of the diseases just listed are only effectively managed when multiple medications spanning different drug classes are employed. Given the multifactorial nature and underlying complexity of AD pathobiology, the expectation that a single agent targeting a single pathological pathway would be highly effective in slowing disease progression seems irrational once different pathologies of varying types are present. In fact, combination strategies have begun to be employed in clinical trial design. The Lilly TRAILBLAZER phase 2 trial initially tested the combination of the BACE1 inhibitor LY3202626 with anti-pyrogutamate A β monoclonal antibody donanemab. Unfortunately, LY3202626 was found to be associated with slight cognitive worsening in dedicated phase 2 trials, so the combination treatment arm was ultimately dropped. Nonetheless, combination strategies in clinical trials should continue to be encouraged, especially those with combinations spanning different drug classes. Ideally, this type of treatment approach would also be applied to preventative or preclinical AD trials.

Conclusions

AD research is at a unique moment. Despite significant advances in our understanding of AD pathobiology, we have not yet identified a disease-modifying therapy that has proven effective in humans. While biochemical analyses, *in vitro* and *in vivo* studies, genetic analyses, and longitudinal imaging studies lend strong support to the role of A β aggregation in initiating disease pathogenesis, the clinical trials as conducted have not panned out. So far, amyloid-based therapeutics appear to be ineffective in modifying the disease course for symptomatic AD. Future clinical trial efforts should instead focus on applying these anti-amyloid treatment strategies to the preclinical disease—the earlier the better—with drugs shown to hit their target effectively. It is now more important than ever to also pursue non-amyloid-based therapies. Tau- and ApoE-directed therapeutics remain at an early stage of development, and both hold great potential going forward. There is also huge potential for therapies that modulate the neuroimmune or microglial response in AD, and this class of drug development is significantly under-represented. Combination therapy is a strategy that should be employed more widely in AD clinical trial design. Finally, AD pathobiology is complex, and the older one is, the greater the likelihood that other age-related diseases contribute to cognitive decline together with AD pathology. Ongoing intensive investigation in this area will be critical to making key discoveries that will ultimately unveil novel therapeutic approaches leading to truly disease-modifying medications.

ACKNOWLEDGMENTS

This work was supported by a grant from the Alzheimer's Association to J.M.L. (AACSF-18-564776) and NIH grants (NS090934, AG047644, and NS074969) as well as grants from the Tau consortium, the JPB Foundation, and Cure Alzheimer's Fund to D.M.H.

AUTHOR CONTRIBUTIONS

Conceptualization, J.M.L. and D.M.H.; Writing – Original Draft, J.M.L.; Writing – Revising & Editing, J.M.L. and D.M.H.; Funding Acquisition, J.M.L. and D.M.H.; Supervision, D.M.H.

DECLARATION OF INTERESTS

J.M.L. reports serving as sub-investigator on the Lilly TRAILBLAZER trial but receives no financial compensation. D.M.H. reports being a co-founder of C2N Diagnostics; being on the scientific advisory board of C2N Diagnostics, Denali, and Genentech; and being a consultant for AbbVie and Idorsia. D.M.H. is an inventor on a submitted patent #PCT/US2013/049333 “Antibodies to tau” that is licensed by Washington University to C2N Diagnostics. This patent was subsequently licensed to AbbVie. D.M.H. is an inventor on patent number 8,591,894 “Humanized antibodies that sequester amyloid beta” that was licensed by Washington University to Eli Lilly. D.M.H. is an inventor on patent number 8,232,107 “Methods for measuring the metabolism of neurally derived biomolecules *in vivo*” that was licensed by Washington University to C2N Diagnostics.

REFERENCES

Abdel-Haq, R., Schlachetzki, J.C.M., Glass, C.K., and Mazmanian, S.K. (2019). Microbiome-microglia connections via the gut-brain axis. *J. Exp. Med.* 276, 41–59.

- ADAPT-FS Research Group (2015). Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study. *Alzheimers Dement.* 11, 216–225.e1.
- Ahmed, Z., Cooper, J., Murray, T.K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M.A., Cavallini, A., Jackson, S., et al. (2014). A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. *Acta Neuropathol.* 127, 667–683.
- Aisen, P.S., Davis, K.L., Berg, J.D., Schafer, K., Campbell, K., Thomas, R.G., Weiner, M.F., Farlow, M.R., Sano, M., Grundman, M., and Thal, L.J. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. *Neurology* 54, 588–593.
- Aisen, P.S., Schafer, K.A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K.L., Farlow, M.R., Jin, S., Thomas, R.G., and Thal, L.J.; Alzheimer's Disease Cooperative Study (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. *JAMA* 289, 2819–2826.
- Altmann, A., Ng, B., Landau, S.M., Jagust, W.J., and Greicius, M.D.; Alzheimer's Disease Neuroimaging Initiative (2015). Regional brain hypometabolism is unrelated to regional amyloid plaque burden. *Brain* 138, 3734–3746.
- Alzheimer's Association (2019). 2019 Alzheimer's disease facts and figures. *Alzheimers Dement.* 15, 321–387.
- Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., and Ikezu, T. (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation. *Nat. Neurosci.* 18, 1584–1593.
- Aschenbrenner, A.J., Gordon, B.A., Benzinger, T.L.S., Morris, J.C., and Hassenstab, J.J. (2018). Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology* 91, e859–e866.
- Atri, A., Frölich, L., Ballard, C., Tariot, P.N., Molinuevo, J.L., Boneva, N., Windfeld, K., Raket, L.L., and Cummings, J.L. (2018). Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. *JAMA* 319, 130–142.
- Bales, K.R., Verina, T., Dodel, R.C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E.M., Little, S.P., Cummins, D.J., et al. (1997). Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. *Nat. Genet.* 17, 263–264.
- Bales, K.R., Verina, T., Cummins, D.J., Du, Y., Dodel, R.C., Saura, J., Fishman, C.E., DeLong, C.A., Piccardo, P., Petegnief, V., et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* 96, 15233–15238.
- Bales, K.R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J.C., Sullivan, P.M., and Paul, S.M. (2009). Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. *J. Neurosci.* 29, 6771–6779.
- Bartus, R.T., Dean, R.L., 3rd, Beer, B., and Lippa, A.S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. *Science* 217, 408–414.
- Basak, J.M., Verghese, P.B., Yoon, H., Kim, J., and Holtzman, D.M. (2012). Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of A β uptake and degradation by astrocytes. *J. Biol. Chem.* 287, 13959–13971.
- Bateman, R.J., Xiong, C., Benzinger, T.L.S., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., et al.; Dominantly Inherited Alzheimer Network (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N. Engl. J. Med.* 367, 795–804.
- Bateman, R.J., Benzinger, T.L., Berry, S., Clifford, D.B., Duggan, C., Fagan, A.M., Fanning, K., Farlow, M.R., Hassenstab, J., McDade, E.M., et al.; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network (2017). The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. *Alzheimers Dement.* 13, 8–19.
- Bäuerl, C., Collado, M.C., Diaz Cuevas, A., Viña, J., and Pérez Martínez, G. (2018). Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan. *Lett. Appl. Microbiol.* 66, 464–471.
- Bell, R.D., Winkler, E.A., Singh, I., Sagare, A.P., Deane, R., Wu, Z., Holtzman, D.M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012). Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* 485, 512–516.
- AD2000 Collaborative Group, Benthall, P., Gray, R., Sellwood, E., Hills, R., Crome, P., and Raftery, J. (2008). Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. *Lancet Neurol.* 7, 41–49.
- Bero, A.W., Yan, P., Roh, J.H., Cirrito, J.R., Stewart, F.R., Raichle, M.E., Lee, J.-M., and Holtzman, D.M. (2011). Neuronal activity regulates the regional vulnerability to amyloid- β deposition. *Nat. Neurosci.* 14, 750–756.
- Bien-Ly, N., Gillespie, A.K., Walker, D., Yoon, S.Y., and Huang, Y. (2012). Reducing human apolipoprotein E levels attenuates age-dependent A β accumulation in mutant human amyloid precursor protein transgenic mice. *J. Neurosci.* 32, 4803–4811.
- Biere, A.L., Ostaszewski, B., Zhao, H., Gillespie, S., Younkin, S.G., and Selkoe, D.J. (1995). Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. *Neurobiol. Dis.* 2, 177–187.
- Biernat, J., Gustke, N., Drewes, G., Mandelkow, E.M., and Mandelkow, E. (1993). Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. *Neuron* 11, 153–163.
- Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst. Rev.* (1), CD005593.
- Boada, M., López, O., Núñez, L., Szczepiorkowski, Z.M., Torres, M., Grifols, C., and Páez, A. (2019). Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. *Alzheimers Dement. (N. Y.)* 5, 61–69.
- Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzog, M.C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., and Jucker, M. (2007). Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. *Am. J. Pathol.* 171, 2012–2020.
- Bourgade, K., Garneau, H., Giroux, G., Le Page, A.Y., Bocti, C., Dupuis, G., Frost, E.H., and Fülöp, T., Jr. (2015). β -Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1. *Biogerontology* 16, 85–98.
- Boxer, A.L., Qureshi, I., Ahljanian, M., Grundman, M., Golbe, L.I., Litvan, I., Honig, L.S., Tuite, P., McFarland, N.R., O'Suilleabhain, P., et al. (2019). Safety of the tau-directed monoclonal antibody BII092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. *Lancet Neurol.* 18, 549–558.
- Braak, H., and Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259.
- Bradshaw, E.M., Chibnik, L.B., Keenan, B.T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L.L., Imboywa, S., Lee, M., Von Korff, A., et al.; Alzheimer Disease Neuroimaging Initiative (2013). CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. *Nat. Neurosci.* 16, 848–850.
- Bridel, C., van Wieringen, W.N., Zetterberg, H., Tijms, B.M., Teunissen, C.E., Alvarez-Cermeño, J.C., Andreasson, U., Axelsson, M., Bäckström, D.C., Bartos, A., et al.; and the NFL Group (2019). Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurol.* Published online June 17, 2019. <https://doi.org/10.1001/jamaneurol.2019.1534>.
- Brier, M.R., Day, G.S., Snyder, A.Z., Tanenbaum, A.B., and Ances, B.M. (2016). N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI. *J. Neurol.* 263, 1083–1091.
- Brody, D.L., Magnoni, S., Schwetye, K.E., Spinner, M.L., Esparza, T.J., Stocchetti, N., Zipfel, G.J., and Holtzman, D.M. (2008). Amyloid-beta dynamics correlate with neurological status in the injured human brain. *Science* 321, 1221–1224.

- Burke, W.J., Miller, J.P., Rubin, E.H., Morris, J.C., Coben, L.A., Ducheck, J., Wittels, I.G., and Berg, L. (1988). Reliability of the Washington University Clinical Dementia Rating. *Arch. Neurol.* 45, 31–32.
- Bussy, A., Snider, B.J., Coble, D., Xiong, C., Fagan, A.M., Cruchaga, C., Benzinger, T.L.S., Gordon, B.A., Hassenstab, J., Bateman, R.J., and Morris, J.C.; Dominantly Inherited Alzheimer Network (2019). Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. *Neurobiol. Aging* 75, 42–50.
- Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015). Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. *Neurology* 84, 2161–2168.
- Buttini, M., Orth, M., Bellosta, S., Akeefe, H., Pitas, R.E., Wyss-Coray, T., Mucke, L., and Mahley, R.W. (1999). Expression of human apolipoprotein E3 or E4 in the brains of ApoE^{-/-} mice: isoform-specific effects on neurodegeneration. *J. Neurosci.* 19, 4867–4880.
- Buttini, M., Masliah, E., Yu, G.-Q., Palop, J.J., Chang, S., Bernardo, A., Lin, C., Wyss-Coray, T., Huang, Y., and Mucke, L. (2010). Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. *Am. J. Pathol.* 177, 563–569.
- Cano-Cuenca, N., Solís-García del Pozo, J.E., and Jordán, J. (2014). Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. *J. Alzheimers Dis.* 38, 155–164.
- Carbone, I., Lazzarotto, T., Ianni, M., Porcellini, E., Forti, P., Masliah, E., Gabrielli, L., and Licastro, F. (2014). Herpes virus in Alzheimer's disease: relation to progression of the disease. *Neurobiol. Aging* 35, 122–129.
- Carlsson, C.M., Gleason, C.E., Hess, T.M., Moreland, K.A., Blazel, H.M., Kosciak, R.L., Schreiber, N.T.N., Johnson, S.C., Atwood, C.S., Pugliese, L., et al. (2008). Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. *J. Alzheimers Dis.* 13, 187–197.
- Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., DeMattos, R.B., Patterson, B.W., Fagan, A.M., Morris, J.C., Mawuenyega, K.G., Cruchaga, C., et al. (2011). Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. *Sci. Transl. Med.* 3, 89ra57.
- Castellano, J.M., Deane, R., Gottesdiener, A.J., Verghese, P.B., Stewart, F.R., West, T., Paoletti, A.C., Kasper, T.R., DeMattos, R.B., Zlokovic, B.V., and Holtzman, D.M. (2012). Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood A β clearance in a mouse model of β -amyloidosis. *Proc. Natl. Acad. Sci. USA* 109, 15502–15507.
- Castellano, J.M., Mosher, K.I., Abbey, R.J., McBride, A.A., James, M.L., Berdnik, D., Shen, J.C., Zou, B., Xie, X.S., Tingle, M., et al. (2017). Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. *Nature* 544, 488–492.
- Cedazo-Minguez, A., Wiehager, B., Winblad, B., Hüttinger, M., and Cowburn, R.F. (2001). Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (A β) and apoE/A β complexes on protein kinase C- α (PKC- α) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. *Neurochem. Int.* 38, 615–625.
- Chang, R., Knox, J., Chang, J., Derbedrossian, A., Vasilevko, V., Cribbs, D., Boado, R.J., Pardridge, W.M., and Sumbria, R.K. (2017). Blood-Brain Barrier Penetrating Biologic TNF- α Inhibitor for Alzheimer's Disease. *Mol. Pharm.* 14, 2340–2349.
- Chen, V.C.-H., Wu, S.-I., Huang, K.-Y., Yang, Y.-H., Kuo, T.-Y., Liang, H.-Y., Huang, K.-L., and Gossop, M. (2018). Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study. *J. Clin. Psychiatry* 79, 16m11312.
- Choi, S.H., Kim, Y.H., Hebisch, M., Sliwinski, C., Lee, S., D'Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014). A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature* 515, 274–278.
- Chou, R.C., Kane, M., Ghimire, S., Gautam, S., and Gui, J. (2016). Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. *CNS Drugs* 30, 1111–1120.
- Cirrito, J.R., Yamada, K.A., Finn, M.B., Sloviter, R.S., Bales, K.R., May, P.C., Schoepp, D.D., Paul, S.M., Mennerick, S., and Holtzman, D.M. (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. *Neuron* 48, 913–922.
- Cirrito, J.R., Kang, J.-E., Lee, J., Stewart, F.R., Verges, D.K., Silverio, L.M., Bu, G., Mennerick, S., and Holtzman, D.M. (2008). Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. *Neuron* 58, 42–51.
- Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A.K., Beibel, M., Staufenbiel, M., et al. (2009). Transmission and spreading of tauopathy in transgenic mouse brain. *Nat. Cell Biol.* 11, 909–913.
- Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R.A., Frank, S., Hench, J., Probst, A., Winkler, D.T., Reichwald, J., Staufenbiel, M., et al. (2013). Brain homogenates from human tauopathies induce tau inclusions in mouse brain. *Proc. Natl. Acad. Sci. USA* 110, 9535–9540.
- Colonna, M., and Butovsky, O. (2017). Microglia Function in the Central Nervous System During Health and Neurodegeneration. *Annu. Rev. Immunol.* 35, 441–468.
- Commissioner, O. of the (2019). Statement from FDA Commissioner Scott Gottlieb, M.D., and Director of FDA's Center for Biologics Evaluation and Research Peter Marks, M.D., Ph.D., cautioning consumers against receiving young donor plasma infusions that are promoted as unproven treatment for varying conditions.
- Congdon, E.E., Wu, J.W., Myeku, N., Figueroa, Y.H., Herman, M., Marinac, P.S., Gestwicki, J.E., Dickey, C.A., Yu, W.H., and Duff, K.E. (2012). Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. *Autophagy* 8, 609–622.
- Cook, C., Carlomagno, Y., Gendron, T.F., Dunmore, J., Scheffel, K., Stetler, C., Davis, M., Dickson, D., Jarpe, M., DeTure, M., and Petrucelli, L. (2014). Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. *Hum. Mol. Genet.* 23, 104–116.
- Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., and Pericak-Vance, M.A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923.
- Coric, V., Salloway, S., van Dyck, C.H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015). Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. *JAMA Neurol.* 72, 1324–1333.
- Crary, J.F., Trojanowski, J.Q., Schneider, J.A., Abisambra, J.F., Abner, E.L., Alafuzoff, I., Arnold, S.E., Attems, J., Beach, T.G., Bigio, E.H., et al. (2014). Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol.* 128, 755–766.
- Crowe, A., James, M.J., Lee, V.M.-Y., Smith, A.B., 3rd, Trojanowski, J.Q., Ballatore, C., and Brunden, K.R. (2013). Aminothenopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. *J. Biol. Chem.* 288, 11024–11037.
- Crowther, R.A., and Wischik, C.M. (1985). Image reconstruction of the Alzheimer paired helical filament. *EMBO J.* 4 (13B), 3661–3665.
- Cruz Hernández, J.C., Bracko, O., Kersbergen, C.J., Muse, V., Haft-Javaherian, M., Berg, M., Park, L., Vinarsik, L.K., Ivasky, I., Rivera, D.A., et al. (2019). Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models. *Nat. Neurosci.* 22, 413–420.
- Da Mesquita, S., Louveau, A., Vaccari, A., Smirnov, I., Cornelison, R.C., King-smore, K.M., Contarino, C., Onengut-Gumuscus, S., Farber, E., Raper, D., et al. (2018). Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. *Nature* 560, 185–191.
- Dawson, H.N., Ferreira, A., Eyster, M.V., Ghoshal, N., Binder, L.I., and Vitek, M.P. (2001). Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. *J. Cell Sci.* 114, 1179–1187.
- de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Pitstick, R., Sahara, N., Ashe, K.H., Carlson, G.A.,

- et al. (2012). Propagation of tau pathology in a model of early Alzheimer's disease. *Neuron* 73, 685–697.
- de Jong, D., Jansen, R., Hoefnagels, W., Jellesma-Eggenkamp, M., Verbeek, M., Borm, G., and Kremer, B. (2008). No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. *PLoS ONE* 3, e1475.
- De Strooper, B. (2014). Lessons from a failed γ -secretase Alzheimer trial. *Cell* 159, 721–726.
- De Strooper, B., and Karran, E. (2016). The Cellular Phase of Alzheimer's Disease. *Cell* 164, 603–615.
- DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., and Holtzman, D.M. (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* 98, 8850–8855.
- DeVos, S.L., Miller, R.L., Schoch, K.M., Holmes, B.B., Kebodeaux, C.S., Wegener, A.J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017). Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. *Sci. Transl. Med.* 9, eaag0481.
- DeVos, S.L., Corjuc, B.T., Oakley, D.H., Nobuhara, C.K., Bannan, R.N., Chase, A., Commins, C., Gonzalez, J.A., Dooley, P.M., Frosch, M.P., and Hyman, B.T. (2018). Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. *Front. Neurosci.* 12, 267.
- Dixit, R., Ross, J.L., Goldman, Y.E., and Holzbaun, E.L.F. (2008). Differential regulation of dynein and kinesin motor proteins by tau. *Science* 319, 1086–1089.
- Dominy, S.S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., et al. (2019). *Porphyromonas gingivalis* in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. *Sci Adv* 5, eaau3333.
- Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R.G., et al.; Alzheimer's Disease Cooperative Study Steering Committee; Semagacestat Study Group (2013). A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N. Engl. J. Med.* 369, 341–350.
- Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P.S., et al.; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N. Engl. J. Med.* 370, 311–321.
- Dumanis, S.B., Tesoriero, J.A., Babus, L.W., Nguyen, M.T., Trotter, J.H., Ladu, M.J., Weeber, E.J., Turner, R.S., Xu, B., Rebeck, G.W., and Hoe, H.S. (2009). ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. *J. Neurosci.* 29, 15317–15322.
- Duyckaerts, C., Delatour, B., and Potier, M.-C. (2009). Classification and basic pathology of Alzheimer disease. *Acta Neuropathol.* 118, 5–36.
- Edison, P., Archer, H.A., Hinz, R., Hammers, A., Pavese, N., Tai, Y.F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. *Neurology* 68, 501–508.
- Efthymiou, A.G., and Goate, A.M. (2017). Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. *Mol. Neurodegener.* 12, 43.
- Egan, M.F., Kost, J., Tariot, P.N., Aisen, P.S., Cummings, J.L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018). Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. *N. Engl. J. Med.* 378, 1691–1703.
- Egan, M.F., Kost, J., Voss, T., Mukai, Y., Aisen, P.S., Cummings, J.L., Tariot, P.N., Vellas, B., van Dyck, C.H., Boada, M., et al. (2019). Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. *N. Engl. J. Med.* 380, 1408–1420.
- Eimer, W.A., Vijaya Kumar, D.K., Navalpur Shanmugam, N.K., Rodríguez, A.S., Mitchell, T., Washicosky, K.J., György, B., Breakefield, X.O., Tanzi, R.E., and Moir, R.D. (2018). Alzheimer's Disease-Associated β -Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. *Neuron* 99, 56–63.e3.
- Eisele, Y.S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L.H., Yan, Z.-X., Roth, K., Aguzzi, A., Staufenbiel, M., Walker, L.C., and Jucker, M. (2009). Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. *Proc. Natl. Acad. Sci. USA* 106, 12926–12931.
- Eisele, Y.S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S.A., Wolburg, H., Walker, L.C., Staufenbiel, M., Heikenwalder, M., and Jucker, M. (2010). Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. *Science* 330, 980–982.
- Eriksen, J.L., Sagi, S.A., Smith, T.E., Weggen, S., Das, P., McLendon, D.C., Ozols, V.V., Jessing, K.W., Zavitz, K.H., Koo, E.H., and Golde, T.E. (2003). NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. *J. Clin. Invest.* 112, 440–449.
- Erny, D., Hrabě de Angelis, A.L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Muhlaker, T., Jakobshagen, K., Buch, T., et al. (2015). Host microbiota constantly control maturation and function of microglia in the CNS. *Nat. Neurosci.* 18, 965–977.
- Ezzat, K., Pernemalm, M., Pålsson, S., Roberts, T.C., Järver, P., Dondalska, A., Bestas, B., Sobkowiak, M.J., Levänen, B., Sköld, M., et al. (2019). The viral protein corona directs viral pathogenesis and amyloid aggregation. *Nat. Commun.* 10, 2331.
- Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.-Y., Dence, C.S., Shah, A.R., LaRossa, G.N., Spinner, M.L., Klunk, W.E., Mathis, C.A., et al. (2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann. Neurol.* 59, 512–519.
- Fagan, A.M., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J.C., and Holtzman, D.M. (2007). Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. *Arch. Neurol.* 64, 343–349.
- Fagan, A.M., Xiong, C., Jasielec, M.S., Bateman, R.J., Goate, A.M., Benzinger, T.L.S., Ghetti, B., Martins, R.N., Masters, C.L., Mayeux, R., et al.; Dominantly Inherited Alzheimer Network (2014). Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Sci. Transl. Med.* 6, 226ra30.
- Feldman, H.H., Doody, R.S., Kivipelto, M., Sparks, D.L., Waters, D.D., Jones, R.W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D.A., and Breazna, A.; LEADe Investigators (2010). Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. *Neurology* 74, 956–964.
- Felsky, D., Roostaei, T., Nho, K., Risacher, S.L., Bradshaw, E.M., Petyuk, V., Schneider, J.A., Saykin, A., Bennett, D.A., and De Jager, P.L. (2019). Neuro-pathological correlates and genetic architecture of microglial activation in elderly human brain. *Nat. Commun.* 10, 409.
- Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., Chiriboga, C.A., Saito, K., Servais, L., Tizzano, E., et al.; ENDEAR Study Group (2017). Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. *N. Engl. J. Med.* 377, 1723–1732.
- Fitzpatrick, A.W.P., Falcon, B., He, S., Murzin, A.G., Murshudov, G., Garringer, H.J., Crowther, R.A., Ghetti, B., Goedert, M., and Scheres, S.H.W. (2017). Cryo-EM structures of tau filaments from Alzheimer's disease. *Nature* 547, 185–190.
- Frost, B., Ollesch, J., Wille, H., and Diamond, M.I. (2009). Conformational diversity of wild-type Tau fibrils specified by templated conformation change. *J. Biol. Chem.* 284, 3546–3551.
- Gale, S.C., Gao, L., Mikacenic, C., Coyle, S.M., Rafaels, N., Murray Dudenkov, T., Madenspacher, J.H., Draper, D.W., Ge, W., Aloor, J.J., et al. (2014). APOE4 is associated with enhanced in vivo innate immune responses in human subjects. *J. Allergy Clin. Immunol.* 134, 127–134.
- Gallardo, G., and Holtzman, D.M. (2017). Antibody Therapeutics Targeting A β and Tau. *Cold Spring Harb. Perspect. Med.* 7, a024331.
- Gan, K.J., and Südhof, T.C. (2019). Specific factors in blood from young but not old mice directly promote synapse formation and NMDA-receptor recruitment. *Proc. Natl. Acad. Sci. USA* 116, 12524–12533.
- Gauthier, S., Feldman, H.H., Schneider, L.S., Wilcock, G.K., Frisoni, G.B., Harlund, J.H., Moebius, H.J., Bentham, P., Kook, K.A., Wischik, D.J., et al. (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients

with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet* 388, 2873–2884.

Gauthier, S., Alam, J., Fillit, H., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M., Salway, S., Sampaio, C., Sims, J.R., Sperling, B., et al. (2019). Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. *J. Prev. Alzheimers Dis.* 6, 164–168.

Giannakopoulos, P., Herrmann, F.R., Bussi re, T., Bouras, C., Kovari, E., Perl, D.P., Morrison, J.H., Gold, G., and Hof, P.R. (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. *Neurology* 60, 1495–1500.

Glenner, G.G., and Wong, C.W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem. Biophys. Res. Commun.* 120, 885–890.

G mez-Isla, T., Price, J.L., McKeel, D.W., Jr., Morris, J.C., Growdon, J.H., and Hyman, B.T. (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. *J. Neurosci.* 16, 4491–4500.

Gordon, B.A., Blazey, T., Su, Y., Fagan, A.M., Holtzman, D.M., Morris, J.C., and Benzinger, T.L.S. (2016). Longitudinal β -Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. *JAMA Neurol.* 73, 1192–1200.

Gordon, B.A., Blazey, T.M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018). Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurol.* 17, 241–250.

Gorno-Tempini, M.L., Brambati, S.M., Ginex, V., Ogar, J., Dronkers, N.F., Marcone, A., Perani, D., Garibotto, V., Cappa, S.F., and Miller, B.L. (2008). The logopenic/phonological variant of primary progressive aphasia. *Neurology* 71, 1227–1234.

G tz, J., Chen, F., van Dorpe, J., and Nitsch, R.M. (2001). Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by A β 42 fibrils. *Science* 293, 1491–1495.

Gratuzze, M., Leyns, C.E.G., and Holtzman, D.M. (2018). New insights into the role of TREM2 in Alzheimer's disease. *Mol. Neurodegener.* 13, 66.

Green, R.C., Schneider, L.S., Amato, D.A., Beelen, A.P., Wilcock, G., Swabb, E.A., and Zavitz, K.H.; Tarenflurbil Phase 3 Study Group (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. *JAMA* 302, 2557–2564.

Greenamyre, J.T., Maragos, W.F., Albin, R.L., Penney, J.B., and Young, A.B. (1988). Glutamate transmission and toxicity in Alzheimer's disease. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 12, 421–430.

Gremer, L., Sch lzel, D., Schenk, C., Reinartz, E., Labahn, J., Ravelli, R.B.G., Tusche, M., Lopez-Iglesias, C., Hoyer, W., Heise, H., et al. (2017). Fibril structure of amyloid- β (1–42) by cryo-electron microscopy. *Science* 358, 116–119.

Griuciuc, A., Serrano-Pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, C.N., Mullin, K., Hooli, B., Choi, S.H., Hyman, B.T., and Tanzi, R.E. (2013). Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron* 78, 631–643.

Griuciuc, A., Patel, S., Federico, A.N., Choi, S.H., Innes, B.J., Oram, M.K., Cereghetti, G., McGinty, D., Anselmo, A., Sadreyev, R.I., et al. (2019). TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease. *Neuron* 103, 820–835.e7.

Grimmer, T., Tholen, S., Yousefi, B.H., Alexopoulos, P., F rschler, A., F rstl, H., Henriksen, G., Klunk, W.E., Mathis, C.A., Perneczky, R., et al. (2010). Progression of cerebral amyloid load is associated with the apolipoprotein E ϵ 4 genotype in Alzheimer's disease. *Biol. Psychiatry* 68, 879–884.

Guo, J.L., Narasimhan, S., Changolkar, L., He, Z., Stieber, A., Zhang, B., Gathagan, R.J., Iba, M., McBride, J.D., Trojanowski, J.Q., and Lee, V.M. (2016). Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. *J. Exp. Med.* 213, 2635–2654.

Guo, T., Noble, W., and Hanger, D.P. (2017). Roles of tau protein in health and disease. *Acta Neuropathol.* 133, 665–704.

Haass, C., Kaether, C., Thinakaran, G., and Sisodia, S. (2012). Trafficking and proteolytic processing of APP. *Cold Spring Harb. Perspect. Med.* 2, a006270.

Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., Fitzgerald, K.A., Latz, E., Moore, K.J., and Golenbock, D.T. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. *Nat. Immunol.* 9, 857–865.

Han, J.-Y., Besser, L.M., Xiong, C., Kukull, W.A., and Morris, J.C. (2019). Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. *Alzheimer Dis. Assoc. Disord.* 33, 87–94.

Hanseeuw, B.J., Betensky, R.A., Jacobs, H.I.L., Schultz, A.P., Sepulcre, J., Becker, J.A., Cosio, D.M.O., Farrell, M., Quiroz, Y.T., Mormino, E.C., et al. (2019). Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. *JAMA Neurol.* Published online June 3, 2019. <https://doi.org/10.1001/jamaneurol.2019.1424>.

Hara, Y., McKeehan, N., and Fillit, H.M. (2019). Translating the biology of aging into novel therapeutics for Alzheimer disease. *Neurology* 92, 84–93.

Hardy, J.A., and Higgins, G.A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science* 256, 184–185.

Harrington, C., Sawchak, S., Chiang, C., Davies, J., Donovan, C., Saunders, A.M., Irizarry, M., Jeter, B., Zvartau-Hind, M., van Dyck, C.H., and Gold, M. (2011). Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. *Curr. Alzheimer Res.* 8, 592–606.

He, Z., Guo, J.L., McBride, J.D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R.J., Yue, C., Dengler, C., et al. (2018). Amyloid- β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. *Nat. Med.* 24, 29–38.

Heckmann, B.L., Teubner, B.J.W., Tummers, B., Boada-Romero, E., Harris, L., Yang, M., Guy, C.S., Zakharenko, S.S., and Green, D.R. (2019). LC3-Associated Endocytosis Facilitates β -Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease. *Cell*.

Heneka, M.T., Kummer, M.P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature* 493, 674–678.

Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., and Romano, G. (2019). Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. *N. Engl. J. Med.* 380, 1483–1485.

Hitt, B.D., Jaramillo, T.C., Chetkovich, D.M., and Vassar, R. (2010). BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. *Mol. Neurodegener.* 5, 31.

Holth, J.K., Fritsch, S.K., Wang, C., Pedersen, N.P., Cirrito, J.R., Mahan, T.E., Finn, M.B., Manis, M., Geerling, J.C., Fuller, P.M., et al. (2019). The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. *Science* eaav2546.

Holtzman, D.M., Pitas, R.E., Kilbridge, J., Nathan, B., Mahley, R.W., Bu, G., and Schwartz, A.L. (1995). Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. *Proc. Natl. Acad. Sci. USA* 92, 9480–9484.

Hong, S., Beja-Glasser, V.F., Nfonoyim, B.M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K.M., Shi, Q., Rosenthal, A., Barres, B.A., et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* 352, 712–716.

Honig, L.S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018). Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. *N. Engl. J. Med.* 378, 321–330.

Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., Carlson, G.A., Lanier, L.M., Yuan, L.-L., et al. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. *Neuron* 68, 1067–1081.

Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., and Bu, G. (2015). Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A β metabolism in apoE4-targeted replacement mice. *Mol. Neurodegener.* 10, 6.

- Huang, Y.A., Zhou, B., Wernig, M., and Südhof, T.C. (2017). ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A β Secretion. *Cell* 168, 427–441.e21.
- Hudry, E., Dashkoff, J., Roe, A.D., Takeda, S., Koffie, R.M., Hashimoto, T., Scheel, M., Spire-Jones, T., Arbel-Ornath, M., Betensky, R., et al. (2013). Gene transfer of human ApoE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. *Sci. Transl. Med.* 5, 212ra161.
- Hunter, J.M., Cirrito, J.R., Restivo, J.L., Kinley, R.D., Sullivan, P.M., Holtzman, D.M., Koger, D., Delong, C., Lin, S., Zhao, L., et al. (2012). Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. *Brain Res.* 1467, 120–132.
- Hurtado, D.E., Molina-Porcel, L., Iba, M., Aboagye, A.K., Paul, S.M., Trojanowski, J.Q., and Lee, V.M.-Y. (2010). Abeta accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. *Am. J. Pathol.* 177, 1977–1988.
- Huynh, T.V., Davis, A.A., Ulrich, J.D., and Holtzman, D.M. (2017a). Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid- β and other amyloidogenic proteins. *J. Lipid Res.* 58, 824–836.
- Huynh, T.V., Liao, F., Francis, C.M., Robinson, G.O., Serrano, J.R., Jiang, H., Roh, J., Finn, M.B., Sullivan, P.M., Esparza, T.J., et al. (2017b). Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β -amyloidosis. *Neuron* 96, 1013–1023.e4.
- Iba, M., Guo, J.L., McBride, J.D., Zhang, B., Trojanowski, J.Q., and Lee, V.M.-Y. (2013). Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. *J. Neurosci.* 33, 1024–1037.
- Iliff, J.J., Wang, M., Liao, Y., Plogg, B.A., Peng, W., Gundersen, G.A., Benveniste, H., Vates, G.E., Deane, R., Goldman, S.A., et al. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β . *Sci. Transl. Med.* 4, 147ra111.
- in 't Veld, B.A., Ruitenber, A., Hofman, A., Launer, L.J., van Duijn, C.M., Stijnen, T., Breteler, M.M., and Stricker, B.H. (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. *N. Engl. J. Med.* 345, 1515–1521.
- Jack, C.R., Jr., and Holtzman, D.M. (2013). Biomarker modeling of Alzheimer's disease. *Neuron* 80, 1347–1358.
- Jack, C.R., Jr., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., et al.; Contributors (2018a). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 14, 535–562.
- Jack, C.R., Jr., Wiste, H.J., Schwarz, C.G., Lowe, V.J., Senjem, M.L., Vemuri, P., Weigand, S.D., Therneau, T.M., Knopman, D.S., Gunter, J.L., et al. (2018b). Longitudinal tau PET in ageing and Alzheimer's disease. *Brain* 141, 1517–1528.
- Jamieson, G.A., Maitland, N.J., Wilcock, G.K., Craske, J., and Itzhaki, R.F. (1991). Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. *J. Med. Virol.* 33, 224–227.
- Jamieson, G.A., Maitland, N.J., Wilcock, G.K., Yates, C.M., and Itzhaki, R.F. (1992). Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. *J. Pathol.* 167, 365–368.
- Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J.D.F., Nicoll, A.J., Kenny, J., Launchbury, F., Linehan, J., Richard-Loendt, A., Walker, A.S., et al. (2015). Evidence for human transmission of amyloid- β pathology and cerebral amyloid angiopathy. *Nature* 525, 247–250.
- Jiang, Q., Lee, C.Y.D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T.M., Collins, J.L., et al. (2008). ApoE promotes the proteolytic degradation of Abeta. *Neuron* 58, 681–693.
- Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Björnsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature* 488, 96–99.
- Ju, Y.S., Ooms, S.J., Sutphen, C., Macauley, S.L., Zangrilli, M.A., Jerome, G., Fagan, A.M., Mignot, E., Zempel, J.M., Claassen, J.A.H.R., and Holtzman, D.M. (2017). Slow wave sleep disruption increases cerebrospinal fluid amyloid- β levels. *Brain* 140, 2104–2111.
- Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., and Malinow, R. (2003). APP processing and synaptic function. *Neuron* 37, 925–937.
- Kang, J.-E., Lim, M.M., Bateman, R.J., Lee, J.J., Smyth, L.P., Cirrito, J.R., Fujiki, N., Nishino, S., and Holtzman, D.M. (2009). Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. *Science* 326, 1005–1007.
- Karch, C.M., and Goate, A.M. (2015). Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol. Psychiatry* 77, 43–51.
- Karran, E., and Hardy, J. (2014). A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. *Ann. Neurol.* 76, 185–205.
- Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. *Nat. Rev. Drug Discov.* 10, 698–712.
- Katsimpardi, L., Litterman, N.K., Schein, P.A., Miller, C.M., Loffredo, F.S., Wojtkiewicz, G.R., Chen, J.W., Lee, R.T., Wagers, A.J., and Rubin, L.L. (2014). Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. *Science* 344, 630–634.
- Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T.K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. *Cell* 169, 1276–1290.e17.
- Kheifets, V., and Braithwaite, S.P. (2019). Plasma-Based Strategies for Therapeutic Modulation of Brain Aging. *Neurotherapeutics* 16, 675–684.
- Kidd, M. (1963). Paired helical filaments in electron microscopy of Alzheimer's disease. *Nature* 197, 192–193.
- Kim, J., Jiang, H., Park, S., Eltorai, A.E.M., Stewart, F.R., Yoon, H., Basak, J.M., Finn, M.B., and Holtzman, D.M. (2011). Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid- β amyloidosis. *J. Neurosci.* 31, 18007–18012.
- Kim, J., Eltorai, A.E.M., Jiang, H., Liao, F., Verghese, P.B., Kim, J., Stewart, F.R., Basak, J.M., and Holtzman, D.M. (2012). Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A β amyloidosis. *J. Exp. Med.* 209, 2149–2156.
- Kinney, J.W., Bemiller, S.M., Murtishaw, A.S., Leisgang, A.M., Salazar, A.M., and Lamb, B.T. (2018). Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement.* (N. Y.) 4, 575–590.
- Knoferle, J., Yoon, S.Y., Walker, D., Leung, L., Gillespie, A.K., Tong, L.M., Bien-Ly, N., and Huang, Y. (2014). Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice. *J. Neurosci.* 34, 14069–14078.
- Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O'Loughlin, E., Xu, Y., Fanek, Z., et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. *Immunity* 47, 566–581.e9.
- Kumar, D.K.V., Choi, S.H., Washicosky, K.J., Eimer, W.A., Tucker, S., Ghofrani, J., Lefkowitz, A., McColl, G., Goldstein, L.E., Tanzi, R.E., and Moir, R.D. (2016). Amyloid- β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. *Sci. Transl. Med.* 8, 340ra72.
- Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., Vronska, M., van der Lee, S.J., Amlie-Wolf, A., et al.; Alzheimer Disease Genetics Consortium (ADGC); European Alzheimer's Disease Initiative (EADI); Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE); Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease Consortium (GERAD/PERADES) (2019). Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat. Genet.* 51, 414–430.

- Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018). Safety, tolerability and immunogenicity of an active anti-A β_{40} vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. *Alzheimers Res. Ther.* **10**, 12.
- Laird, F.M., Cai, H., Savonenko, A.V., Farah, M.H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V.E., et al. (2005). BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. *J. Neurosci.* **25**, 11693–11709.
- Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M.G.M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D.W., et al.; NILVAD Study Group (2018). Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. *PLoS Med.* **15**, e1002660.
- Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, S.H., Sahara, N., Skipper, L., Yager, D., et al. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science* **293**, 1487–1491.
- Leyns, C.E.G., Ulrich, J.D., Finn, M.B., Stewart, F.R., Koscal, L.J., Remolina Serrano, J., Robinson, G.O., Anderson, E., Colonna, M., and Holtzman, D.M. (2017). TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. *Proc. Natl. Acad. Sci. USA* **114**, 11524–11529.
- Leyns, C.E.G., Gratzu, M., Narasimhan, S., Jain, N., Koscal, L.J., Jiang, H., Manis, M., Colonna, M., Lee, V.M.Y., Ulrich, J.D., and Holtzman, D.M. (2019). TREM2 function impedes tau seeding in neuritic plaques. *Nat. Neurosci.* **22**, 1217–1222.
- Liao, F., Hori, Y., Hudry, E., Bauer, A.Q., Jiang, H., Mahan, T.E., Lefton, K.B., Zhang, T.J., Dearborn, J.T., Kim, J., et al. (2014). Anti-ApoE antibody given after plaque onset decreases A β accumulation and improves brain function in a mouse model of A β amyloidosis. *J. Neurosci.* **34**, 7281–7292.
- Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M.B., Hoyle, R., Keyser, J., Lefton, K.B., et al. (2018). Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. *J. Clin. Invest.* **128**, 2144–2155.
- Liddel, S.A., Guttenplan, K.A., Clarke, L.E., Bennett, F.C., Bohlen, C.J., Schirmer, L., Bennett, M.L., Münch, A.E., Chung, W.-S., Peterson, T.C., et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* **541**, 481–487.
- Lippens, G., and Gigant, B. (2019). Elucidating Tau function and dysfunction in the era of cryo-EM. *J. Biol. Chem.* **294**, 9316–9325.
- Liu, L., Drouet, V., Wu, J.W., Witter, M.P., Small, S.A., Clelland, C., and Duff, K. (2012). Trans-synaptic spread of tau pathology in vivo. *PLoS ONE* **7**, e31302.
- Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., and Bu, G. (2017). ApoE4 Accelerates Early Seeding of Amyloid Pathology. *Neuron* **96**, 1024–1032.e3.
- Liu, L., Ding, L., Rovere, M., Wolfe, M.S., and Selkoe, D.J. (2019). A cellular complex of BACE1 and γ -secretase sequentially generates A β from its full-length precursor. *J. Cell Biol.* **218**, 644–663.
- Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S.G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017). Dementia prevention, intervention, and care. *Lancet* **390**, 2673–2734.
- Logovinsky, V., Satlin, A., Lai, R., Swanson, C., Kaplow, J., Osswald, G., Basun, H., and Lannfelt, L. (2016). Safety and tolerability of BAN2401—a clinical study in Alzheimer's disease with a protofibril selective A β antibody. *Alzheimers Res. Ther.* **8**, 14.
- Lopez Lopez, C., Tariot, P.N., Caputo, A., Langbaum, J.B., Liu, F., Riviere, M.-E., Langlois, C., Rouzade-Dominguez, M.-L., Zalesak, M., Hendrix, S., et al. (2019). The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. *Alzheimers Dement.* (N. Y.) **5**, 216–227.
- Lovestone, S., Boada, M., Dubois, B., Hüll, M., Rinne, J.O., Huppertz, H.-J., Calero, M., Andrés, M.V., Gómez-Carrillo, B., León, T., and del Ser, T.; ARGO investigators (2015). A phase II trial of tideglusib in Alzheimer's disease. *J. Alzheimers Dis.* **45**, 75–88.
- Lowe, V.J., Lundt, E.S., Albertson, S.M., Przybelski, S.A., Senjem, M.L., Parisi, J.E., Kantarci, K., Boeve, B., Jones, D.T., Knopman, D., et al. (2019). Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. *Alzheimers Dement.* **15**, 927–939.
- Lucey, B.P., Hicks, T.J., McLeland, J.S., Toedebusch, C.D., Boyd, J., Elbert, D.L., Patterson, B.W., Baty, J., Morris, J.C., Ovod, V., et al. (2018). Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. *Ann. Neurol.* **83**, 197–204.
- Mandelkow, E., von Bergen, M., Biernat, J., and Mandelkow, E.-M. (2007). Structural principles of tau and the paired helical filaments of Alzheimer's disease. *Brain Pathol.* **17**, 83–90.
- Marcelli, S., Corbo, M., Iannuzzi, F., Negri, L., Blandini, F., Nistico, R., and Feligioni, M. (2018). The Involvement of Post-Translational Modifications in Alzheimer's Disease. *Curr. Alzheimer Res.* **15**, 313–335.
- Martiskainen, H., Herukka, S.-K., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., and Hiltunen, M. (2017). Decreased plasma β -amyloid in the Alzheimer's disease APP A673T variant carriers. *Ann. Neurol.* **82**, 128–132.
- Masters, C.L., and Selkoe, D.J. (2012). Biochemistry of amyloid β -protein and amyloid deposits in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* **2**, a006262.
- Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci. USA* **82**, 4245–4249.
- Matarin, M., Salih, D.A., Yasvoina, M., Cummings, D.M., Guelfi, S., Liu, W., Nahaboo Solim, M.A., Moens, T.G., Paublete, R.M., Ali, S.S., et al. (2015). A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. *Cell Rep.* **10**, 633–644.
- Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J.Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019). Single-cell transcriptomic analysis of Alzheimer's disease. *Nature* **570**, 332–337.
- Mattsson, N., Cullen, N.C., Andreasson, U., Zetterberg, H., and Blennow, K. (2019). Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol.* **76**, 791–799.
- McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* **7**, 263–269.
- McShane, R., Areosa Sastre, A., and Minakaran, N. (2006). Memantine for dementia. *Cochrane Database Syst. Rev.* (2), CD003154.
- Meyer, P.-F., Tremblay-Mercier, J., Leoutsakos, J., Madjar, C., Lafaille-Maignan, M.-É., Savard, M., Rosa-Neto, P., Poirier, J., Etienne, P., and Breitner, J.; PREVENT-AD Research Group (2019). INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. *Neurology* **92**, e2070–e2080.
- Middeldorp, J., Lehallier, B., Villeda, S.A., Miedema, S.S.M., Evans, E., Czirz, E., Zhang, H., Luo, J., Stan, T., Mosher, K.I., et al. (2016). Preclinical Assessment of Young Blood Plasma for Alzheimer Disease. *JAMA Neurol.* **73**, 1325–1333.
- Mielke, M.M., Syrjanen, J.A., Blennow, K., Zetterberg, H., Vemuri, P., Skoog, I., Machulda, M.M., Kremers, W.K., Knopman, D.S., Jack, C., Jr., et al. (2019). Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. *Neurology* **93**, e252–e260.
- Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W.W., Huang, E.J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. *Neuron* **67**, 953–966.
- Minter, M.R., Zhang, C., Leone, V., Ringus, D.L., Zhang, X., Oyler-Castrillo, P., Musch, M.W., Liao, F., Ward, J.F., Holtzman, D.M., et al. (2016). Antibiotic-

- induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. *Sci. Rep.* 6, 30028.
- Mishra, S., Blazey, T.M., Holtzman, D.M., Cruchaga, C., Su, Y., Morris, J.C., Benzinger, T.L.S., and Gordon, B.A. (2018). Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ϵ 4 genotype. *Brain* 141, 1828–1839.
- Moir, R.D., Lathe, R., and Tanzi, R.E. (2018). The antimicrobial protection hypothesis of Alzheimer's disease. *Alzheimers Dement.* 14, 1602–1614.
- Morris, J.C. (1997). Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int. Psychogeriatr.* 9 (Suppl 1), 173–176, discussion 177–178.
- Morris, J.C. (2019). Editorial: Is Now the Time for Combination Therapies for Alzheimer Disease? *J. Prev. Alzheimers Dis.* 6, 153–154.
- Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Holtzman, D.M., and Mintun, M.A. (2009). Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. *Arch. Neurol.* 66, 1469–1475.
- Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M., and Mintun, M.A. (2010). APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann. Neurol.* 67, 122–131.
- Musiek, E.S., and Holtzman, D.M. (2015). Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. *Nat. Neurosci.* 18, 800–806.
- Najm, R., Jones, E.A., and Huang, Y. (2019). Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer's disease. *Mol. Neurodegener.* 14, 24.
- Nakamura, A., Kaneko, N., Villemagne, V.L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018). High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature* 554, 249–254.
- Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., and Ikeda, K. (1991). Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. *Brain Res.* 541, 163–166.
- Nathan, B.P., Bellosta, S., Sanan, D.A., Weisgraber, K.H., Mahley, R.W., and Pitas, R.E. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. *Science* 264, 850–852.
- Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., Castellani, R.J., Crain, B.J., Davies, P., Del Tredici, K., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J. Neuropathol. Exp. Neurol.* 71, 362–381.
- Nicoll, J.A.R., Buckland, G.R., Harrison, C.H., Page, A., Harris, S., Love, S., Neal, J.W., Holmes, C., and Boche, D. (2019). Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. *Brain* 142, 2113–2126.
- Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019). Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes. *Science* 365, eaav9518.
- Novak, P., Zilka, N., Zilkova, M., Kovacech, B., Skrabana, R., Ondrus, M., Fialova, L., Kontseikova, E., Otto, M., and Novak, M. (2019). AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development. *J. Prev. Alzheimers Dis.* 6, 63–69.
- Nuriel, T., Angulo, S.L., Khan, U., Ashok, A., Chen, Q., Figueroa, H.Y., Emrani, S., Liu, L., Herman, M., Barrett, G., et al. (2017). Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology. *Nat. Commun.* 8, 1464.
- Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T.S., Mori, K., Nakayama, T., Ihara, Y., and Takeda, M. (2013). γ -secretase modulators and presenilin 1 mutants act differently on presenilin-1/ γ -secretase function to cleave A β 42 and A β 43. *Cell Rep.* 3, 42–51.
- Olsson, M., Årlig, J., Hedner, J., Blennow, K., and Zetterberg, H. (2018). Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. *Sleep (Basel)* 41. <https://doi.org/10.1093/sleep/zsy025>.
- Ooms, S., Overeem, S., Besse, K., Rikkert, M.O., Verbeek, M., and Claassen, J.A.H.R. (2014). Effect of 1 night of total sleep deprivation on cerebrospinal fluid β -amyloid 42 in healthy middle-aged men: a randomized clinical trial. *JAMA Neurol.* 71, 971–977.
- Ossenkoppele, R., Pijnenburg, Y.A.L., Perry, D.C., Cohn-Sheehy, B.I., Scheltens, N.M.E., Vogel, J.W., Kramer, J.H., van der Vlies, A.E., La Joie, R., Rosen, H.J., et al. (2015). The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. *Brain* 138, 2732–2749.
- Ostrowitzki, S., Lasser, R.A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar, P., et al.; SCArlet RoAD Investigators (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. *Alzheimers Res. Ther.* 9, 95.
- Ou-Yang, M.-H., Kurz, J.E., Nomura, T., Popovic, J., Rajapaksha, T.W., Dong, H., Contractor, A., Chetkovich, D.M., Tourtellotte, W.G., and Vassar, R. (2018). Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. *Sci. Transl. Med.* 10, eaao5620.
- Ovod, V., Ramsey, K.N., Mawuenyega, K.G., Bollinger, J.G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D.M., Morris, J.C., et al. (2017). Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimers Dement.* 13, 841–849.
- Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., and Hansson, O. (2019). Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. *JAMA Neurol.* Published online June 24, 2019. <https://doi.org/10.1001/jamaneurol.2019.1632>.
- Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018). BACE inhibitors in clinical development for the treatment of Alzheimer's disease. *Expert Rev. Neurother.* 18, 847–857.
- Parhizkar, S., Arzberger, T., Brendel, M., Kleinberger, G., Deussing, M., Focke, C., Nuscher, B., Xiong, M., Ghasemigharagooz, A., Katzmarski, N., et al. (2019). Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. *Nat. Neurosci.* 22, 191–204.
- Pascoal, T.A., Mathotaarachchi, S., Kang, M.S., Mohaddes, S., Shin, M., Park, A.Y., Parent, M.J., Benedet, A.L., Chamoun, M., Theriault, J., et al. (2019). A β -induced vulnerability propagates via the brain's default mode network. *Nat. Commun.* 10, 2353.
- Peters, F., Salihoglu, H., Rodrigues, E., Herzog, E., Blume, T., Filser, S., Dorostkar, M., Shimshek, D.R., Brose, N., Neumann, U., and Herms, J. (2018). BACE1 inhibition more effectively suppresses initiation than progression of β -amyloid pathology. *Acta Neuropathol.* 135, 695–710.
- Pontecorvo, M.J., Devous, M.D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P.M., Southekal, S., Arora, A.K., et al. (2019). A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. *Brain* 142, 1723–1735.
- Pooler, A.M., Polydoro, M., Maury, E.A., Nicholls, S.B., Reddy, S.M., Wegmann, S., William, C., Sagran, L., Cagsal-Getkin, O., Pitstick, R., et al. (2015). Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. *Acta Neuropathol. Commun.* 3, 14.
- Preisich, O., Schultz, S.A., Apel, A., Kuhle, J., Kaeser, S.A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., Laske, C., et al.; Dominantly Inherited Alzheimer Network (2019). Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nat. Med.* 25, 277–283.
- Price, J.L., and Morris, J.C. (1999). Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann. Neurol.* 45, 358–368.
- Price, J.L., McKeel, D.W., Jr., Buckles, V.D., Roe, C.M., Xiong, C., Grundman, M., Hansen, L.A., Petersen, R.C., Parisi, J.E., Dickson, D.W., et al. (2009). Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. *Neurobiol. Aging* 30, 1026–1036.
- Purro, S.A., Farrow, M.A., Linehan, J., Nazari, T., Thomas, D.X., Chen, Z., Mengel, D., Saito, T., Saido, T., Rudge, P., et al. (2018). Transmission of amyloid- β

- protein pathology from cadaveric pituitary growth hormone. *Nature* 564, 415–419.
- Qi, Y., Klyubin, I., Cuello, A.C., and Rowan, M.J. (2018). NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo. *Neurobiol. Dis.* 114, 24–30.
- Rajapaksha, T.W., Eimer, W.A., Bozza, T.C., and Vassar, R. (2011). The Alzheimer's β -secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. *Mol. Neurodegener.* 6, 88.
- Readhead, B., Haure-Mirande, J.-V., Funk, C.C., Richards, M.A., Shannon, P., Haroutunian, V., Sano, M., Liang, W.S., Beckmann, N.D., Price, N.D., et al. (2018). Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. *Neuron* 99, 64–82.e7.
- Reiman, E.M., Langbaum, J.B.S., Fleisher, A.S., Caselli, R.J., Chen, K., Ayutyanont, N., Quiroz, Y.T., Kosik, K.S., Lopera, F., and Tariot, P.N. (2011). Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of pre-symptomatic treatments. *J. Alzheimers Dis.* 26 (Suppl 3), 321–329.
- Relkin, N.R., Thomas, R.G., Rissman, R.A., Brewer, J.B., Rafii, M.S., van Dyck, C.H., Jack, C.R., Sano, M., Knopman, D.S., Raman, R., et al.; Alzheimer's Disease Cooperative Study (2017). A phase 3 trial of IV immunoglobulin for Alzheimer disease. *Neurology* 88, 1768–1775.
- Risacher, S.L., Kim, S., Nho, K., Foroud, T., Shen, L., Petersen, R.C., Jack, C.R., Jr., Beckett, L.A., Aisen, P.S., Koeppe, R.A., et al.; Alzheimer's Disease Neuroimaging Initiative (ADNI) (2015). APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. *Alzheimers Dement.* 11, 1417–1429.
- Roh, J.H., Huang, Y., Bero, A.W., Kasten, T., Stewart, F.R., Bateman, R.J., and Holtzman, D.M. (2012). Disruption of the sleep-wake cycle and diurnal fluctuation of β -amyloid in mice with Alzheimer's disease pathology. *Sci. Transl. Med.* 4, 150ra122.
- Rosenberg, J.B., Kaplitt, M.G., De, B.P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R.J., Monette, S., et al. (2018). AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. *Hum. Gene Ther. Clin. Dev.* 29, 24–47.
- Roses, A.D. (1996). Apolipoprotein E alleles as risk factors in Alzheimer's disease. *Annu. Rev. Med.* 47, 387–400.
- Ryan, P., Xu, M., Davey, A.K., Danon, J.J., Mellick, G.D., Kassiou, M., and Rudrawar, S. (2019). O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. *ACS Chem. Neurosci.* 10, 2209–2221.
- Saji, N., Niida, S., Murotani, K., Hisada, T., Tsuduki, T., Sugimoto, T., Kimura, A., Toba, K., and Sakurai, T. (2019). Analysis of the relationship between the gut microbiome and dementia: a cross-sectional study conducted in Japan. *Sci. Rep.* 9, 1008.
- Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P., Ferris, S., et al.; Bapineuzumab 301 and 302 Clinical Trial Investigators (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. *N. Engl. J. Med.* 370, 322–333.
- Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A., Barker, S.J., Foley, A.C., Thorpe, J.R., Serpell, L.C., et al. (2014). Distinct tau prion strains propagate in cells and mice and define different tauopathies. *Neuron* 82, 1271–1288.
- Sano, M., Bell, K.L., Galasko, D., Galvin, J.E., Thomas, R.G., van Dyck, C.H., and Aisen, P.S. (2011). A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. *Neurology* 77, 556–563.
- Sato, C., Barthélemy, N.R., Mawuenyega, K.G., Patterson, B.W., Gordon, B.A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M.J., Kasten, T., Kirmess, K.M., et al. (2018). Tau Kinetics in Neurons and the Human Central Nervous System. *Neuron* 97, 1284–1298.e7.
- Sayed, F.A., Telpoukhovskaia, M., Kodama, L., Li, Y., Zhou, Y., Le, D., Hauduc, A., Ludwig, C., Gao, F., Clelland, C., et al. (2018). Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. *Proc. Natl. Acad. Sci. USA* 115, 10172–10177.
- Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 400, 173–177.
- Schultz, S.A., Gordon, B.A., Mishra, S., Su, Y., Perrin, R.J., Cairns, N.J., Morris, J.C., Ances, B.M., and Benzinger, T.L.S. (2018). Widespread distribution of tauopathy in preclinical Alzheimer's disease. *Neurobiol. Aging* 72, 177–185.
- Selkoe, D.J. (2019). Alzheimer disease and aducanumab: adjusting our approach. *Nat. Rev. Neurol.* 15, 365–366.
- Selkoe, D.J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol. Med.* 8, 595–608.
- Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M.B., Gich, I., Agulló, J.M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009). A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. *Neurobiol. Dis.* 35, 359–367.
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P.H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016). The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature* 537, 50–56.
- Sha, S.J., Deutsch, G.K., Tian, L., Richardson, K., Coburn, M., Gaudioso, J.L., Marcal, T., Solomon, E., Boumis, A., Bet, A., et al. (2019). Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial. *JAMA Neurol.* 76, 35–40.
- Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., and Sabatini, B.L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J. Neurosci.* 27, 2866–2875.
- Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* 14, 837–842.
- Shi, Y., and Holtzman, D.M. (2018). Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. *Nat. Rev. Immunol.* 18, 759–772.
- Shi, Y., Yamada, K., Liddel, S.A., Smith, S.T., Zhao, L., Luo, W., Tsai, R.M., Spina, S., Grinberg, L.T., Rojas, J.C., et al.; Alzheimer's Disease Neuroimaging Initiative (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature* 549, 523–527.
- Sohn, P.D., Tracy, T.E., Son, H.-I., Zhou, Y., Leite, R.E.P., Miller, B.L., Seeley, W.W., Grinberg, L.T., and Gan, L. (2016). Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. *Mol. Neurodegener.* 11, 47.
- Song, W.M., Joshita, S., Zhou, Y., Ulland, T.K., Gilfillan, S., and Colonna, M. (2018). Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. *J. Exp. Med.* 215, 745–760.
- Soscia, S.J., Kirby, J.E., Washicosky, K.J., Tucker, S.M., Ingelsson, M., Hyman, B., Burton, M.A., Goldstein, L.E., Duong, S., Tanzi, R.E., and Moir, R.D. (2010). The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. *PLoS ONE* 5, e9505.
- Sosna, J., Philipp, S., Albay, R., 3rd, Reyes-Ruiz, J.M., Baglietto-Vargas, D., LaFerla, F.M., and Glabe, C.G. (2018). Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease. *Mol. Neurodegener.* 13, 11.
- Spangenberg, E., Severson, P.L., Hohsfield, L.A., Crapser, J., Zhang, J., Burton, E.A., Zhang, Y., Spevak, W., Lin, J., Phan, N.Y., et al. (2019). Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. *Nat. Commun.* 10, 3758.
- Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., and Aisen, P. (2014). The A4 study: stopping AD before symptoms begin? *Sci. Transl. Med.* 6, 228f13.

- Spitzer, P., Condic, M., Herrmann, M., Oberstein, T.J., Scharin-Mehlmann, M., Gilbert, D.F., Friedrich, O., Grömer, T., Kornhuber, J., Lang, R., and Maler, J.M. (2016). Amyloidogenic amyloid- β -peptide variants induce microbial agglutination and exert antimicrobial activity. *Sci. Rep.* 6, 32228.
- Stephenson, D., Perry, D., Bens, C., Bain, L.J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., et al. (2015). Charting a path toward combination therapy for Alzheimer's disease. *Expert Rev. Neurother.* 15, 107–113.
- Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., and Roses, A.D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 90, 1977–1981.
- Strittmatter, W.J., Saunders, A.M., Goedert, M., Weisgraber, K.H., Dong, L.M., Jakes, R., Huang, D.Y., Pericak-Vance, M., Schmechel, D., and Roses, A.D. (1994). Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 91, 11183–11186.
- Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L.E., and Song, W. (2006). Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. *Proc. Natl. Acad. Sci. USA* 103, 18727–18732.
- Tabrizi, S.J., Leavitt, B.R., Landwehrmeyer, G.B., Wild, E.J., Saft, C., Barker, R.A., Blair, N.F., Craufurd, D., Priller, J., Rickards, H., et al.; Phase 1–2a IONIS-HTTRx Study Site Teams (2019). Targeting Huntingtin Expression in Patients with Huntington's Disease. *N. Engl. J. Med.* 380, 2307–2316.
- Tang-Wai, D.F., Graff-Radford, N.R., Boeve, B.F., Dickson, D.W., Parisi, J.E., Crook, R., Caselli, R.J., Knopman, D.S., and Petersen, R.C. (2004). Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. *Neurology* 63, 1168–1174.
- Tariot, P.N., Lopera, F., Langbaum, J.B., Thomas, R.G., Hendrix, S., Schneider, L.S., Rios-Romenets, S., Giraldo, M., Acosta, N., Tobon, C., et al.; Alzheimer's Prevention Initiative (2018). The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical *PSEN1* E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. *Alzheimers Dement.* (N. Y.) 4, 150–160.
- Tcw, J., and Goate, A.M. (2017). Genetics of β -Amyloid Precursor Protein in Alzheimer's Disease. *Cold Spring Harb. Perspect. Med.* 7, a024539.
- Thal, L.J., Ferris, S.H., Kirby, L., Block, G.A., Lines, C.R., Yuen, E., Assaid, C., Nessly, M.L., Norman, B.A., Baranak, C.C., and Reines, S.A.; Rofecoxib Protocol 078 study group (2005). A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. *Neuropsychopharmacology* 30, 1204–1215.
- Tzeng, N.-S., Chung, C.-H., Lin, F.-H., Chiang, C.-P., Yeh, C.-B., Huang, S.-Y., Lu, R.-B., Chang, H.-A., Kao, Y.-C., Yeh, H.-W., et al. (2018). Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections—a Nationwide, Population-Based Cohort Study in Taiwan. *Neurotherapeutics* 15, 417–429.
- Ulrich, J.D., Finn, M.B., Wang, Y., Shen, A., Mahan, T.E., Jiang, H., Stewart, F.R., Piccio, L., Colonna, M., and Holtzman, D.M. (2014). Altered microglial response to A β plaques in APPPS1-21 mice heterozygous for TREM2. *Mol. Neurodegener.* 9, 20.
- Ulrich, J.D., Ulland, T.K., Mahan, T.E., Nyström, S., Nilsson, K.P., Song, W.M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., et al. (2018). ApoE facilitates the microglial response to amyloid plaque pathology. *J. Exp. Med.* 215, 1047–1058.
- van der Lee, S.J., Conway, O.J., Jansen, I., Carrasquillo, M.M., Kleindam, L., van den Akker, E., Hernández, I., van Eijk, K.R., Stringa, N., Chen, J.A., et al.; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB); GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer's Disease) Study Group (2019). A nonsynonymous mutation in *PLCG2* reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. *Acta Neuropathol.* 138, 237–250.
- van Hummel, A., Bi, M., Ippati, S., van der Hoven, J., Volkerling, A., Lee, W.S., Tan, D.C.S., Bongers, A., Ittner, A., Ke, Y.D., and Ittner, L.M. (2016). No Overt Deficits in Aged Tau-Deficient C57Bl/6.Maptm1(EGFP)Kit GFP Knockin Mice. *PLoS ONE* 11, e0163236.
- Vandenberghe, R., Riviere, M.-E., Caputo, A., Sovago, J., Maguire, R.P., Farlow, M., Marotta, G., Sanchez-Valle, R., Scheltens, P., Ryan, J.M., and Graf, A. (2016). Active A β immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. *Alzheimers Dement.* (N. Y.) 3, 10–22.
- Varga, A.W., Wohlleber, M.E., Giménez, S., Romero, S., Alonso, J.F., Ducca, E.L., Kam, K., Lewis, C., Tanzi, E.B., Tweardy, S., et al. (2016). Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A β 42 Levels in Cognitively Normal Elderly. *Sleep (Basel)* 39, 2041–2048.
- Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., et al. (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science* 286, 735–741.
- Vellas, B., Black, R., Thal, L.J., Fox, N.C., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., Grundman, M., et al. (2009). Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. *Curr. Alzheimer Res.* 6, 144–151.
- Venegas, C., Kumar, S., Franklin, B.S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M.P., et al. (2017). Microglia-derived ASC specks cross-seed amyloid- β in Alzheimer's disease. *Nature* 552, 355–361.
- Verges, D.K., Restivo, J.L., Goebel, W.D., Holtzman, D.M., and Cirrito, J.R. (2011). Opposing synaptic regulation of amyloid- β metabolism by NMDA receptors *in vivo*. *J. Neurosci.* 31, 11328–11337.
- Verghese, P.B., Castellano, J.M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., and Holtzman, D.M. (2013). ApoE influences amyloid- β (A β) clearance despite minimal apoE/A β association in physiological conditions. *Proc. Natl. Acad. Sci. USA* 110, E1807–E1816.
- Vermunt, L., Sikkes, S.A.M., van den Hout, A., Handels, R., Bos, I., van der Flier, W.M., Kern, S., Ousset, P.-J., Maruff, P., Skoog, I., et al. (2019). Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimers Dement.* 15, 888–898.
- Villeda, S.A., Plambeck, K.E., Middeldorp, J., Castellano, J.M., Mosher, K.I., Luo, J., Smith, L.K., Bieri, G., Lin, K., Berdnik, D., et al. (2014). Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. *Nat. Med.* 20, 659–663.
- Vlad, S.C., Miller, D.R., Kowall, N.W., and Felson, D.T. (2008). Protective effects of NSAIDs on the development of Alzheimer disease. *Neurology* 70, 1672–1677.
- Vogt, N.M., Kerby, R.L., Dill-McFarland, K.A., Harding, S.J., Merluzzi, A.P., Johnson, S.C., Carlsson, C.M., Asthana, S., Zetterberg, H., Blennow, K., et al. (2017). Gut microbiome alterations in Alzheimer's disease. *Sci. Rep.* 7, 13537.
- Vos, S.J., Xiong, C., Visser, P.J., Jasielec, M.S., Hassenstab, J., Grant, E.A., Cairns, N.J., Morris, J.C., Holtzman, D.M., and Fagan, A.M. (2013). Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. *Lancet Neurol.* 12, 957–965.
- Voytyuk, I., De Strooper, B., and Chávez-Gutiérrez, L. (2018). Modulation of γ - and β -Secretases as Early Prevention Against Alzheimer's Disease. *Biol. Psychiatry* 83, 320–327.
- Wagner, S.L., Rynearson, K.D., Duddy, S.K., Zhang, C., Nguyen, P.D., Becker, A., Vo, U., Masliah, D., Monte, L., Klee, J.B., et al. (2017). Pharmacological and Toxicological Properties of the Potent Oral γ -Secretase Modulator BPN-15606. *J. Pharmacol. Exp. Ther.* 362, 31–44.
- Walker, L.C., and Jucker, M. (2015). Neurodegenerative diseases: expanding the prion concept. *Annu. Rev. Neurosci.* 38, 87–103.

- Wang, C., Najm, R., Xu, Q., Jeong, D.-E., Walker, D., Balestra, M.E., Yoon, S.Y., Yuan, H., Li, G., Miller, Z.A., et al. (2018). Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. *Nat. Med.* **24**, 647–657.
- Wang, L., Benzinger, T.L., Su, Y., Christensen, J., Friedrichsen, K., Aldea, P., McConathy, J., Cairns, N.J., Fagan, A.M., Morris, J.C., et al. (2016). Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β -Amyloid and Tauopathy. *JAMA Neurol.* **73**, 1070–1077.
- Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, T.E., Murphy, M.P., Bulters, T., et al. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. *Nature* **414**, 212–216.
- Wei, W., Nguyen, L.N., Kessels, H.W., Hagiwara, H., Sisodia, S., and Malinow, R. (2010). Amyloid beta from axons and dendrites reduces local spine number and plasticity. *Nat. Neurosci.* **13**, 190–196.
- Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., and Kirschner, M.W. (1975). A protein factor essential for microtubule assembly. *Proc. Natl. Acad. Sci. USA* **72**, 1858–1862.
- West, T., Hu, Y., Verghese, P.B., Bateman, R.J., Braunstein, J.B., Fogelman, I., Budur, K., Florian, H., Mendonca, N., and Holtzman, D.M. (2017). Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. *J. Prev. Alzheimers Dis.* **4**, 236–241.
- Willem, M., Garratt, A.N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., and Haass, C. (2006). Control of peripheral nerve myelination by the beta-secretase BACE1. *Science* **314**, 664–666.
- Wischik, C.M., Edwards, P.C., Lai, R.Y., Roth, M., and Harrington, C.R. (1996). Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. *Proc. Natl. Acad. Sci. USA* **93**, 11213–11218.
- Wozniak, M.A., Mee, A.P., and Itzhaki, R.F. (2009). Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. *J. Pathol.* **217**, 131–138.
- Xia, W. (2019). γ -Secretase and its modulators: Twenty years and beyond. *Neurosci. Lett.* **701**, 162–169.
- Xie, L., Kang, H., Xu, Q., Chen, M.J., Liao, Y., Thiyagarajan, M., O'Donnell, J., Christensen, D.J., Nicholson, C., Iliff, J.J., et al. (2013). Sleep drives metabolite clearance from the adult brain. *Science* **342**, 373–377.
- Yaffe, K., Laffan, A.M., Harrison, S.L., Redline, S., Spira, A.P., Ensrud, K.E., Ancoli-Israel, S., and Stone, K.L. (2011). Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. *JAMA* **306**, 613–619.
- Yamada, K., Holth, J.K., Liao, F., Stewart, F.R., Mahan, T.E., Jiang, H., Cirrito, J.R., Patel, T.K., Hochgräfe, K., Mandelkow, E.-M., et al. (2014). Neuronal activity regulates extracellular tau *in vivo*. *J. Exp. Med.* **211**, 387–393.
- Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E., Wozniak, D.F., Diamond, M.I., and Holtzman, D.M. (2013). Anti-tau antibodies that block tau aggregate seeding *in vitro* markedly decrease pathology and improve cognition *in vivo*. *Neuron* **80**, 402–414.
- Yanamandra, K., Jiang, H., Mahan, T.E., Maloney, S.E., Wozniak, D.F., Diamond, M.I., and Holtzman, D.M. (2015). Anti-tau antibody reduces insoluble tau and decreases brain atrophy. *Ann. Clin. Transl. Neurol.* **2**, 278–288.
- Yanamandra, K., Patel, T.K., Jiang, H., Schindler, S., Ulrich, J.D., Boxer, A.L., Miller, B.L., Kerwin, D.R., Gallardo, G., Stewart, F., et al. (2017). Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. *Sci. Transl. Med.* **9**, eaal2029.
- Yang, G., Zhou, R., Zhou, Q., Guo, X., Yan, C., Ke, M., Lei, J., and Shi, Y. (2019). Structural basis of Notch recognition by human γ -secretase. *Nature* **565**, 192–197.
- Ye, L., Fritsch, S.K., Schelle, J., Obermüller, U., Degenhardt, K., Kaeser, S.A., Eisele, Y.S., Walker, L.C., Baumann, F., Staufenbiel, M., et al. (2015). Persistence of A β seeds in APP null mouse brain. *Nat. Neurosci.* **18**, 1559–1561.
- Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A.A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell* **153**, 707–720.
- Zhao, N., Liu, C.-C., Van Ingelgom, A.J., Linares, C., Kurti, A., Knight, J.A., Heckman, M.G., Diehl, N.N., Shinohara, M., Martens, Y.A., et al. (2018). APOE ϵ 2 is associated with increased tau pathology in primary tauopathy. *Nat. Commun.* **9**, 4388.
- Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., and Shi, Y. (2019). Recognition of the amyloid precursor protein by human γ -secretase. *Science* **363**, eaaw0930.
- Zlokovic, B.V. (2013). Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. *JAMA Neurol.* **70**, 440–444.